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 Since the treatment of infections with antibiotics, Staphylococcus aureus has 
developed resistance to antimicrobial agents. Methicillin-resistant S aureus (MRSA) 
contributes significantly to the healthcare burden of both hospital and community 
infections. Investigation into the resistance mechanism and their inhibition has the 
potential to increase the effectiveness in treating infection. It is hypothesized that the 
diversity of compounds and efficacy found in complex natural product extracts would 
lead to active leads that inhibit bacterial resistance.  Using synergistic activity testing as 
a guide to a fractionation process, 3 flavonoids (8-desmethyl-sideroxylin, sideroxylin, 
and 6-desmethyl-sideroxlyn) were identified as synergists within a Hydrastis canadensis 
extract.  These compounds were further characterized as efflux pump inhibitors using 
fluorescence in real-time and under confocal microscopy. In addition to disrupting 
efflux, the ability of S. aureus to cause disease was investigated.  By detecting auto-
inducing peptide I (AIP I), a direct product in the activation of this pathway, inhibition via 
natural products could be determined. Disruption in the intercellular communication via 
the Agr quorum sensing pathway in MRSA was observed in a Penicillium fungus and in H. 
canadensis.  This quorum sensing inhibition (quorum quenching) limits virulence and 
toxin production making it easier for the host to manage infection. 
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CHAPTER I 
 
REVIEW OF LITERTURE OF STAPHYLOCOCCUS AUREUS AND ITS MECHANISMS OF  
 
RESISTANCE 
 
 
 Staph infections are a significant source of morbidity, mortality, and health care 
costs in our society.  In 2007, the Centers for Disease Control and Prevention estimated 
the direct cost of hospital-acquired infections in the United States was close to $45 
billion and expected to rise.    Of these infections over 20% were from methicillin-
resistant strains of Staphylococcus aureus.1   The incidence of resistant strains of S. 
aureus has risen significantly in the past 50 years, paralleling the development of novel 
antibiotics.2  Since the development of penicillin in the 1940s, strains of S. aureus have 
developed ever-evolving defense mechanisms to disable, inactivate, and expel nearly 
every commercially available antibacterial.   Therefore, novel strategies, including 
combination of antibiotics and adjunctive therapies are needed to treat these 
increasingly resistant infections. 
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1.1 Pathogenesis of S. aureus 
 
S. aureus is a Gram-positive bacterium that is naturally resistant to desiccation 
and does not produce spores like many other Gram-positive species. S. aureus can 
survive in a variety of conditions including human skin and favors a saline environment. 
In fact, approximately 30% of the general population’s normal skin flora includes 
S.aureus.3   S. aureus may be transmitted via direct contact with contaminated skin or 
via a contaminated surface.4  Once inoculated beneath the human epidermis, S. aureus 
can become a formidable human pathogen.5  Enzymes within the bacteria catalyze the 
conversion of soluble fibrinogen to insoluble fibrin, which causes the blood around the 
bacterium to clot in order to create a physical barrier to protect the bacterium from 
host defense.6  
 In addition to the production of physical barriers to block host defense 
mechanisms, S. aureus produces a series of virulence factors that facilitate toxin 
production and promote its pathogenesis.  The extracellular toxins consist of alpha-, 
beta-, gamma- and delta-hemolysin, general enterotoxins, and toxic shock syndrome 
toxin 1.  Toxic shock syndrome causes hypotension, shock, organ failure, and fever.  The 
other toxins can cause necrotizing pneumonia in children through the disruption of 
eukaryotic cell membranes.7 
3 
 
1.2 History of MRSA as a nosocomial pathogen 
Studies have shown the appearance of resistant S. aureus has come in four large 
distinct waves as a response to the increased implementation of certain antibiotics of 
the time.  The first wave was penicillin resistant and came as a result of the overuse of 
the drug as a treatment of infections in hospitals in the 1940s.  The second wave 
appeared in response to methicillin producing the MRSA strains in the early 1960s. The 
third wave was a new MRSA strain that spread worldwide in the 1970s significantly 
increasing the overall healthcare burden of Staphylococcus infections.  The final wave 
began in the 1990s and consists of the transference of hospital-acquired Staphylococcus 
infections to the community causing significant outbreaks in specific areas. This 
community acquired MRSA strain (CA-MRSA) added a significant burden to the 
healthcare system due to its wide spread prevalence and resistance to typical antibiotic 
treatment.  Although initially susceptible to most antibiotics, CA-MRSA has continued to 
increase its resistance and is expected to become more difficult to treat within the next 
decade.8 9 10 
 Hospital-acquired Gram-positive infections became a significant problem 
beginning in the 1940, and were first thought to be isolated incidents.11 However, by the 
1950s, the prevalence of staphylococcal infections had increased to the point that 
outbreaks were widely reported in the medical press.12  Penicillin resistance was 
reported as early as 1955, thus encouraging the development of novel antibiotics.13 
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 Methicillin, a synthetic penicillin derivative, was introduced in the 1950s to 
target penicillin resistant strains of bacteria; however, resistance to methicillin was 
recorded by the end of the decade.14 Furthermore, these strains of methicillin-resistant 
S. aureus (MRSA) were also resistant to cephalosporins, cloxacillin, and dicloxacillin.  
Nevertheless, prevalence of these MRSA strains remained low, and the majority of S. 
aureus strains remained susceptible to antibiotics through the 1970’s. 15   MRSA did not 
receive significant press and remained obscure until several well publicized outbreaks 
occurred in the 1980s and 1990s. 8  
 Initial medical reports of MRSA infections suggested that MRSA was a weakly 
virulent pathogen and posed no greater threat to health than other hospital-acquired 
infections.  MRSA was labeled as weakly pathogenic, and few resources were devoted to 
development of new treatment strategies given the low abundance of reported cases.16  
More recently, however, there have been numerous reports in the literature of bacterial 
infection from MRSA; all highlighting one theme: the inability of standard infection-
prevention precautions to control outbreaks of MRSA despite its relatively low 
virulence.17 18 19 
  Beginning in the 1990s, there were widespread international hospital-based 
outbreaks of MRSA infections leading to increased attention from the scientific and 
medical communities.  It became apparent that increasing resistance patterns among S. 
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aureus strains had resulted from repeated exposure of S. aureus to broad-spectrum 
antibiotics allowing for hyper-mutation and selection of the most resistant organism.20 
Thus, the term ‘MRSA’ was developed to refer to a heterogeneous group of bacteria 
with multiple different mechanisms for antimicrobial resistance including antibiotic 
expulsion and inactivation.21  In addition, the growing diversity of MRSA strains 
facilitated the sharing of resistance producing genes through plasmid exchange which 
allowed for the evolution of even more virulent and sturdy strains of MRSA. Further 
studies of these MRSA strains including those performed by Casewell and Hill showed 
the emergent strains to be highly virulent.  Casewell and Hill showed that under the 
right conditions MRSA could achieve full pathogenic potential, leading to severe 
systemic infection as opposed to colonization as was first thought.22 
1.3 S. aureus: A present-problem 
 Presently, S. aureus is one of the leading causes of hospital acquired infections, 
with MRSA infection specifically growing each year.  In fact, S. aureus is the primary 
source of hospital-acquired respiratory tract infections and infections in sites in which 
surgery was performed.  It is also the second leading cause for nosocomial pneumonia 
and cardiovascular infections.23 Due to the increasing resistance to treatment, MRSA 
infections have become extremely difficult to treat.  
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Across the United States, hospital-acquired MRSA has become a significant 
problem, especially in long-term care facilities and intensive care units.24 25 26  In the 
year 2000, 43.2% (125,969) of all S. aureus infections were determined to be methicillin-
resistant.27 From 1999-2005 the number of infections caused by S. aureus increased 62% 
from 294,570 to 477,927.28 In the same study, the number of MRSA-related 
hospitalizations more than doubled (127,036 – 278,203), and the incidence of MRSA 
surgical site infections and MRSA pneumonia more than tripled.29  Since 2005 the MRSA 
infections have continued to rise with total infections increasing to 463,017 in 2009 - 
almost doubling within 4 years.30 Additionally, CA-MRSA has become increasingly 
prevalent amongst groups living in close quarters such as day care facilities, military 
barracks, and college campuses.25 From 2005 to 2009 the number of incidents of CA-
MRSA infections have more than doubled 70,432 to 152,000. Unlike hospital-acquired 
MRSA, CA-MRSA has caused more episodic localized outbreaks in various communities.  
These outbreaks have been more difficult to eradicate due to the colonization of larger 
populations, which has significantly increased the cost of treating CA-MRSA.31   
The direct cost of S. aureus infections acquired in the hospital has been 
estimated to be > $6 billion.32  Drug-resistant infections pose an even greater cost when 
compared to general susceptible infections.  These resistant infections prolong illness, 
increase mortality, and increase direct health care cost by 30-100%.33  MRSA infections, 
when compared to methicillin sensitive S. aureus (MSSA), can increase the direct cost of 
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treatment of a single infection $3,000 - $35,000.  Without taking into account the 
indirect costs of infection, MRSA alone cost the healthcare system an estimated $830 
million - $9.7 billion in 2005.34 
1.4 Resistance mechanisms and epidemiology of S. aureus  
 
 Resistance in S. aureus results from many different factors.   Mutations in 
common resistance genes can have a profound impact on antimicrobial uptake, 
degradation, augmentation, and export.  Also, the exchange of genetic information 
between microorganisms can spread the expression of resistant genes throughout a 
population of bacteria.  Furthermore, certain environmental conditions, especially those 
found in hospital settings, can facilitate the spread of resistant organisms. Exposure to 
various antibiotics preferentially selects for resistant bacteria which are able to survive 
and reproduce. Thus, treatment with broad spectrum antibiotics can indirectly facilitate 
the spread of resistant clones across a large human population.35 
As S. aureus replicates, uncorrected base substitutions of the copied DNA occur 
randomly at a frequency of 10-9 to 10-10 per gene, leading to a possible expression or 
deletion of individual genes.36  This allows the bacteria to express new proteins which 
may exhibit antibacterial resistance. Expression of these proteins can result in 
breakdown or augmentation of antibiotics, up-regulation of efflux systems, or down-
regulation of uptake pathways.37  
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Scientists initially posited that bacteria would develop resistance solely from 
mutation events at the chromosomal level, and thus mutations would be a rare event.38 
However, it was determined that some mutations in preexisting resistance genes 
enhanced resistance.  These genes, when activated are not specific to a certain 
antibiotic, but provide a generic defense to toxic compounds by turning on a series of 
defense-related proteins which expands the range of resistance. As a result, a minor 
mutation could lead to an up-regulation of a protein responsible for the activation of a 
series of preexisting defense mechanisms and render a bacterium resistant to multiple 
antibiotics from a single gene mutation. For example, β-lactamases that initially only 
provided resistance to penicillin and ampicillin, and through a mutation, became 
capable of hydrolyzing not only basic penicillins but also extended-spectrum 
cephalosporins and monobactams.39   This type of mutation has been shown to increase 
the resistance of bacteria in a single hospital during a period of 2 years by 50% as 
compared to theoretical resistance calculated via general mutation statistics.40  
In the 1980s, scientists discovered S. aureus had the ability to exchange genetic 
information across different species of bacteria.41  Like other Gram-positive bacteria, 
transduction and transformation are the primary forms of genetic exchange in S. 
aureus.42  For example, S. aureus and Staphylococcus epidermis have been shown to 
share aminoglycoside resistance across species.43  Although resistance genes were 
determined to be transferred amongst different species of bacteria, expression is not 
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always maintained, and the case in which resistance is not expressed is not fully 
understood.44 However, the bacteria can acquire resistance genes from other 
organisms, including the natural bacterial flora of the gut, and the potential of cross-
species transfer of resistance mechanisms could lead to a more rapid development of 
resistance in S. aureus. 
One strategy to combat the ever increasing resistance of the staphylococci 
bacteria is the development of new drugs.  However, resistance mechanisms often 
appear soon after widespread administration of a new antibiotic.  For example, when 
vancomycin was developed, it was used frequently to treat MRSA infections.   The heavy 
use of this antibiotic created a selective pressure, environmental conditions promoting 
resistance to develop in a bacterium, which encouraged the development and spread of 
resistance to the drug in the 1990s.45   Vancomycin was used in hospitals, long-term care 
facilities, agricultural sites, and day-cares, which all increased the selective pressure.  
Whether resistance was acquired due to a spontaneous mutation or the exchange of 
genetic information across species is unknown; however, the level of resistance has 
been shown to be directly correlated to the intensity of use of an antibiotic.46 Normally, 
vancomycin has a minimum inhibitory concentration (MIC) against S. aureus of 1-4 
µg/mL; however, a subpopulation of S. aureus has become resistant to vancomycin up 
to concentrations of 8 µg/mL.47  Thus, new antimicrobial strategies, such as drug 
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combination or directly attacking resistance mechanisms, are needed in treatment of 
resistant S. aureus infections other than increasing antibiotic use. 
1.5 The role of multidrug efflux pumps in resistance 
 
 A significant way S. aureus becomes resistant to antimicrobial agents is through 
the expression of multi-resistant phenotypes, which impart resistance to multiple 
antibiotic classes. One such multi-resistant phenotype is the expression of multi-drug 
resistant (MDR) efflux pumps, transmembrane proteins that actively transport 
metabolites outside the cell. Efflux pumps have the potential to remove a variety of 
antimicrobial agents.48  Although efflux-mediated resistances have been overlooked in 
the past, recently there has been an increased interest due to their ability to provide 
broad-spectrum resistance in S. aureus.   It is hypothesized that inhibition of MDR efflux 
pumps in S. aureus, would lead to increased efficacy of antimicrobial compounds at 
lower concentrations. By limiting the diversity of resistant mechanisms through the 
inhibition of efflux pumps in S. aureus, more treatment options for infections would be 
available. 49   
 Efflux pumps in bacteria play a physiological role in removing toxic metabolites 
produced by the cells, exporting of virulence factors during pathogenesis, and 
responding to cell stress.  The expulsion of antimicrobial agents, therefore, is said to be 
a secondary mode of action of these pumps. Efflux pumps can exhibit specificity 
towards a particular antimicrobial agent or class of antimicrobial agents; however, they 
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can also have a broad range of antimicrobial compounds that they remove from the cell.  
Efflux pumps are able to act on a wide range of substrates which has enabled the 
bacteria to apply the efflux pump mechanism to a wide range of antimicrobial 
compounds.  Furthermore, stress to the bacteria has been shown to increase the 
expression of these pumps allowing for increased resistance.50   
1.6 Chromosomal multidrug efflux pumps 
 
 There are five families of multidrug resistance (MDR) efflux pumps that are 
separated based on the energy requirement needed to actively efflux outside the 
bacterial cell.  They are the major facilitator super-family (MFS); the small multidrug 
resistance family (SMR); the multidrug and toxic compound extrusion family (MATE); the 
resistance-nodulation-cell division super-family (RND); and the adenosine-triphosphate 
(ATP)-binding cassette (ABC) super-family.   The MATE family uses a proton or sodium 
membrane gradient to drive the export of its substrates, whereas the MFS, SMR, RND 
use the proton mode of force to drive efflux.  As the name suggests, the ABC super-
family uses ATP as the energy needed to actively transport its substrates outside the 
cell.51 
 The most studied chromosomally-encoded MDR pump in S. aureus is the NorA 
efflux pump, which is part of the MFS class of pumps. The NorA efflux pump accounts 
for the majority of broad spectrum resistance in S. aureus through its overexpression 
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and its ability to efflux multiple antimicrobial compounds. In fact the NorA efflux pump 
is overexpressed in almost all resistant strains of S. aureus isolated from blood 
infections.52   
 The norA gene consists of three alleles that have up to a 10% difference in 
sequence.53  The norA gene is a 388 amino acid transmembrane protein containing 12 
segments.54  The NorA pump effluxes a variety of dissimilar compounds such as 
fluoroquinolones, dyes, and quaternary ammonium compounds.55 The expression of the 
norA gene can be induced through activation of regulatory proteins or mutations in the 
norA promoter region.56   
 Like all of the efflux pumps belonging to the MFS, NorA uses a proton motive 
force via an H+ anti-port mechanism to transport antimicrobial compounds outside the 
cell.  By taking in 2 protons, the pump is able to export an intercellular substrate outside 
the cell against a concentration gradient.  This mode of action was determined through 
using a proton motive force disrupter, carbonyl m-chlorophenylhydrazone (CCCP).  CCCP 
disrupts the proton motive force by dissipating the proton gradient which has been 
shown to inhibit the efflux of norfoxacin and ethidium bromide via the NorA efflux 
pump.57 
 In S. aureus the NorB and the NorC efflux pump systems are structurally similar 
to the NorA system.  NorB is a proton dependent pump of the MFS composed of 463 
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amino acids and 12 transmembrane segments with a 30% complementary sequence to 
that of NorA.58   The antimicrobial substrates for NorB include all of the NorA substrates 
plus tetracycline and hydrophobic fluoroquinolones such as moxifloxacin and 
sparfloxacin.59  The NorC pump is a 462 amino acid protein consisting of 12 
transmembrane portions with a 61% complementation to NorB.60  Overexpression of 
the norC gene can be induced when S. aureus is exposed to hypoxemic or acidic 
conditions such as those found in shock.61 Substrates similar to the NorB pump as well 
as garenoxacin and rhodamine have been shown to be substrates of the NorC efflux 
pump.62 
 Recently, a new efflux pump was discovered in S. aureus that resulted from a 
norA mutation.63   This new efflux pump, known as MepA, is the first MDR pump 
classified as part of the MATE family to be found in S. aureus.  MepA consists of 451 
amino acids with 12 transmembrane segments and its antimicrobial substrates include 
quaternary ammonium compounds, ethidium bromide, and some glycyclines.64 
 Another chromosomal MDR found in S. aureus is MdeA.  This efflux pump 
consists of 479 amino acids with 14 transmembrane segments and is classified into the 
MFS.  Activation of the MdeA gene leads to resistance against dequalinium, 
benzalkonium, ethidium bromide, virginiamycin, novobiocin, and fusidic acid with 
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fluroquinones being weak substrates. It has been shown expression of MdeA can be 
induced by a mutation on the MdeA promoter region.65 
 The SepA pump is another chromosomal MDR classified into the SMR family 
found in S. aureus. Some argue it belongs in a new type of family based on its 
dissimilarity in protein structure.  It consists of 157 amino acids with 4 transmembrane 
segments which is characteristic of the SMR family; however, residues important for 
substrate specificity are located in completely different parts of the protein compared 
to the rest of this class.  The SepA pump has not been studied in detail, but it has been 
shown to add low level resistance to antiseptic compounds in S. aureus.66   
 This dissertation will focus on the inhibition of the NorA efflux pump specifically. 
Although there have been many different types of efflux pumps identified in S. aureus, 
studies have shown inhibition of the NorA to significantly enhance the antimicrobial 
effects of many different compounds.105 Providing the S. aureus with a broad range of 
resistance, overexpression of this pump has significantly lowered the efficacy of 
currently used drugs.   Through its increased prevalence in clinical isolates of MRSA, 
inhibition research on this pump is relevant and needed. 
1.7 Assessing efflux activity  
 
 Measuring the decrease in the MIC of current antibiotics with the addition of 
potential efflux pump inhibitors (EPIs) allows determination of whether certain 
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compounds disrupt the expulsion of antimicrobial agents outside the cell.67  MIC is the 
concentration of an antimicrobial agent needed to inhibit the growth of the bacteria 
with lower values indicating more potent an antimicrobial agents.  The presence of 
known EPIs have been shown to lower the MIC values of many antimicrobial agents; 
however, this assay fails to describe whether an EPI inhibits a specific efflux pump or has 
a more general antimicrobial effect.  One of the limitations of this approach in assessing 
inhibition of efflux in S. aureus is the diversity of MDR pumps. A particular inhibitor can 
have varying degrees of inhibition which complicates the mechanism of action at the 
cellular level.68 
 A different approach for identifying possible EPIs has been to use ethidium 
bromide, a fluorescent dye, which is a substrate for most MDR efflux pumps in S. 
aureus.   By measuring extracellular concentrations of the dye both with and without 
the potential EPI one can determine the net effect of the candidate compound.69  Also, 
ethidium bromide has been used in the cartwheel method, which measures the amount 
of ethidium bromide inside a cell after overnight incubation.70 Ethidium bromide has 
also been reported to be used to measure efflux activity directly using real-time 
fluorometry, which will be its primary use in this dissertation.71 
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1.8 Quorum sensing in S. aureus 
 
 Quorum sensing, which allows adjacent organisms to communicate via 
intercellular signaling, is another potential target for novel compounds that disable the 
harmful effects of a bacterial infection.  This form of communication across bacteria 
cells has been shown to be important in virulence of S. aureus.   Virulence for a bacterial 
species includes the route of entry into the host, the number of bacteria present, the 
general effect on the host’s defense mechanism, and the types of virulence factors 
produced.   Virulence factors are typically proteins synthesized by enzymes trigging a 
cascade effect promoting toxin production and pathogenesis.  These virulence factors 
are an intrinsic property to the quorum sensing pathway in S. aureus. By specifically 
inhibiting the production of virulence factors it is possible to disrupt the intercellular 
communication and limit the ability of the bacteria to cause disease.  By decreasing 
virulence antimicrobial treatments become more effective at eradicating an infection, 
and thus prevent a population of bacteria to develop resistance. 
1.9 Natural products as a possible source to combat bacterial resistance 
 
 From poultices to teas to salves, a variety of natural products from plants, 
animals, and fungi have been used to treat ailments since before the development of 
modern medicine. In the past significant research went into the discovery of 
constituents within natural products that lead to a desired biological activity.  Between 
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1981 and 2002, almost half (49%) of the 877 new small molecule drugs developed in the 
United States were either natural products, semi-synthetic natural product analogs, or 
synthetic compounds based on a natural-product structure.72  Natural herbal remedies 
have been a major source bioactive compounds because they are considered to have 
stood the test of time, to have little toxicity, and to be relatively easily obtained at low 
costs.73   
Since the 1990s pharmaceutical research into natural products has been on the 
decline.  This decline can be attributed to both specific technologic advances in drug 
research and overall change of the economic climate of drug development. The advent 
of high-throughput screening assays has encouraged testing of synthetic known 
compounds as opposed to natural product extracts.  Additionally, increases in molecular 
targets discovered from advances in molecular biology and genomics have shortened 
drug discovery timelines. Also, major drug companies have largely shifted away from 
antimicrobial compounds to focus on more lucrative chronic illnesses such as diabetes, 
heart disease, and cancer.74  Nevertheless, recent trends into natural remedies coupled 
with the underwhelming production of new drug therapies from commercial 
pharmaceutical companies has sparked a renewed interest in the chemical diversity that 
can be found in natural products.75 
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It is important to note the decreased emphasis on natural product research in 
the past twenty years has not been due to a lack of potential drug targets. Research into 
the diversity of compounds found in antimicrobial natural product extracts has been 
revived as a result of the increased burden that MRSA and other resistant bacteria are 
having on the healthcare system.  Specifically, extracts in which antimicrobial 
compounds have been isolated are being reevaluated in pursuit of possible synergistic 
effects of undiscovered constituents.  The diversity of compounds in these extracts has 
the potential to be bioactive against new targets of resistance.76 
1.10 Research objective 
 
 S. aureus resistance has dramatically increased due to rapid evolution in 
response to increased in antibiotic use and hyper-mutation.  As resistance and virulence 
increases, the cost and burden on society increases as well.  New strategies to combat 
this growing problem are needed to help relieve this global healthcare burden.  
Investigation of the biodiversity of secondary metabolites from natural products 
represents an exciting possible solution. By analyzing antimicrobial properties of 
historically used natural products and identifying possible synergists, it may be possible 
to find a new approach to address growing resistance.   In this dissertation, different 
strategies are discussed and evaluated in vitro against various strains of S. aureus to 
demonstrate possible solutions to limit virulence and inhibit resistance mechanisms.  
19 
 
The overall goal is to illustrate possible strategies to combat antimicrobial resistant S. 
aureus through the use of secondary metabolites found in natural products.   
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CHAPTER II 
SYNERGY-GUIDED FRACTIONATION TO INDENTIFY ANTIMICROBIAL POTENTIATORS  
 
FROM A COMPLEX HYDRASTIS CANADENSIS EXTRACT 
 
2.1 Abstract 
 
Rationale: The objective of this study was to identify and characterize synergy within 
various Hydrastis canadensis root and leaf extracts by adapting a checkerboard assay 
traditionally used for single drug combinations.  Using this new assay, we sought to 
determine whether commercial preparations of the leaf or the root portion of the plant 
had a greater synergistic effect.  Also, we implemented synergy testing to guide the 
isolation of synergists from a large chloroform extract. 
Methods: S. aureus NCTC 8325-477 was used and characterized by a growth curve. 
Hydrastis canadensis plant samples were collected at Bearwallow Ginseng in 
Hendersonville, North Carolina.  Pooled extracts were prepared using 100 g of 
root/rhizome material and 100 g of aerial portions in 50% ethanol extract.   Berberine in 
the pooled ethanol extracts and a crude chloroform extract were quantified.  
Combinations of the pooled ethanol extracts and the chloroform aerial extract were 
standardized based on the concentration of berberine and tested using a checkerboard 
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assay.  Fractions from the crude chloroform extract were tested against the original 
chloroform extract to determine which extracts exhibited synergy. Subsequent fractions 
of the aerial chloroform were tested for synergistic activity and the most active fraction 
was fractionated into sub fractions and tested form synergistic activity. 
Results:  The pooled ethanol extract of the aerial portion of the plant exhibited synergy 
with a FIC Index value of 0.375 and crude chloroform extract, Fraction 3, and Sub 
Fraction 2 exhibited a synergistic effect when tested via the checkerboard assay with FIC 
Index values of 0.19, 0.13, and 0.03 respectively.  The pooled ethanol extract of the 
root/rhizome and berberine alone exhibited an additive effect in the checkerboard 
assay with FIC Index values of 0.75 and 1.0 respectively.  Fraction 3 and Sub Fraction 2 
were characterized as potentiators by having no antimicrobial effect alone at their 
maximal concentrations that could be solubilized.   
Conclusions: By standardizing a complex Hydrastis canadensis extract to a single known 
compound within the extract, synergy testing can be utilized. Through this methodology 
the root portion of the Hydrastis canadensis had a lower synergistic effect than the 
aerial portion of the plant which contained potentiators that could be identified via 
synergy-guided fractionation.   
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2.2 Introduction 
 
 Antimicrobial synergy is defined as a greater antimicrobial outcome observed for 
two drugs used in combination compared to the expected antimicrobial effect when 
each drug’s individual efficacy is summed at the same concentration.78 Thus, if Drug A 
and Drug B were tested for antimicrobial synergy and had a theoretical antimicrobial 
effect of 1 each, and if the overall effect of Drug A plus Drug B was greater than 2, then 
Drug A and Drug B would be synergist for the reason that 1+1 > 2.  Moreover, if Drug A 
theoretically had no individual antimicrobial effect alone, yet when combined with Drug 
B had a net efficacy greater than Drug B’s individual efficacy, then Drug A would be 
characterized as a potentiator, a specific type of synergist which enhances the overall 
effect, but has no effect of its own.79 In this case 0 + 1 > 1. In determining synergistic 
effects in antimicrobial studies, efficacy can be measured through the minimum 
inhibitory concentrations (MICs) of the individual drugs and the combination of those 
drugs in a checkerboard assay.    
 Synergism between two compounds can be identified qualitatively and 
quantitatively assessed by varying the concentrations of the two compounds of interest 
and measuring their combined efficacy.  Traditionally in an antimicrobial study, a 
checkerboard assay is used in which varying concentrations of Drug A and Drug B are 
used and percent activity assessed.  Efficacy can then be plotted in an graph detailing 
the interaction between drugs called an isobologram, and based on the curvature; the 
effect of the combination of the drugs tested can be determined to be synergistic, 
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additive, or antagonistic as shown in Figure 1. Furthermore, by assessing the fractional 
inhibitory concentrations of each component, a quantitative value can be assigned to 
the individual efficacies of each drug.  By summing the fractional inhibitory 
concentrations the fractional inhibitory concentration index (FIC index) can be 
calculated as shown in the below equation: 
 
(Equation 1) 
 
 
If the calculated FIC Index is less than 0.5, then the interaction between drug A and B is 
characterized as a synergistic effect.  If the value is between 0.5 and 1.0, the interaction 
is characterized as additive effect, and any value greater than 1.0 the interaction is 
characterized as antagonistic effect.80 
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Figure 1. Isobologram of two drugs to evaluate possible combination effects. 
 
 
 In the area of alternative medicine, efficacy of complex extracts has been argued 
to be the result of the combined activity of multiple components working in synergy.  It 
is hypothesized implementing a checkerboard assay on chloroform and an ethanol 
extract of Hydrastis canadensis can determine if synergistic activity exists between 
components of plant.   Tinctures and salves of Hydrastis canadensis, commonly referred 
to as Goldenseal, have historically been used by Iroquois to treat ailments ranging from 
eyesores and skin infections, to dysentery and upset stomach.81 82 83 More recently, 
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extracts from H. canadensis have been shown to have an antimicrobial effect against S. 
aureus. This antimicrobial effect has largely been attributed to the alkaloid found in the 
plant called berberine shown in Figure 2, which has been shown to intercalate with the 
DNA of the bacteria preventing basic cell function.84 . This compound has been shown to 
be effective at inhibiting the growth of Gram-positive and Gram-negative bacteria 85 
Today, Hydrastis canadensis is used as a botanical medicine to combat inflammation 
and infection.  The plant extracts are popular in the international market86 87 and is 
ranked twelfth among the top selling botanical dietary supplements in the US88.  
Typically the roots are more commonly used medicinally because of their higher alkaloid 
content89, although H. canadensis leaves have also been used for medicinal purposes. Its 
antimicrobial properties have led to increased cultivation, which destroys the plant 
leading to  a decrease on the H. canadensis population. 
 
 
Figure 2. Structure of the alkaloid berberine found in Hydrastis canadensis. 
  
26 
 
 The goals of the research described in this chapter are  to apply the 
checkerboard assay to a complex extracts of Hydrastis canadensis to characterize the 
interaction of the complex extracts and berberine as synergistic, additive, or 
antagonistic, to further test different extracted portions of the plant (leaf and root), and 
to test fractions of the chloroform extract against the crude to guide the isolation 
process to indentify individual synergists  By standardizing the berberine within the 
extract, the extract can be treated as an individual component (Drug A) in the 
checkerboard assay, and it is then possible to observe the interactions between 
fractions of the extract and the extract itself to determine whether synergy exists 
between components of the plant. 
2.3 Experimental 
2.3.1 S. aureus preparation 
 
A single colony of wild-type S. aureus (NCTC 8325-4) was incubated in 5.00 mL of 
Müeller-Hinton broth for a 24-hr period. After incubation, it was added to 50.0 mL 
Müeller-Hinton broth in a 150 mL Erlenmeyer flask to make a stock solution. The optical 
density at 600 nm (OD600) of the stock solution was measured using a Spectrometer 20 
and was designated as the OD600 at time T = 0. To measure colony forming units (CFU) 
of this original bacterial solution, a 100 μL aliquot of the original stock solution was 
diluted with 900 μL PBS in an Eppendorf tube, which resulted in a 1.00 × 10
-1 
dilution 
(A). After preparing solution A, the original stock solution was incubated at 37
o
C while 
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shaking at 200 rpm. Then from solution A, a series of 10-fold dilutions were performed, 
giving 1.0 × 10
-2 
(B), 1.0 ×10
-3 
(C), 1.0 × 10
-4 
(D), 1.0 × 10
-5 
(E), and 1.0 × 10
-6 
(F) dilutions 
of the stock solution. Each dilution of the bacteria was grown in agar plate. A 100 μL 
solution was spread evenly across an agar plate while spinning the Petri dish with a 
small rotating circular platform. The growth plate was prepared in duplicate for each 
dilution and incubated for 24 hr at 37
o
C.  The colony forming units (CFU) in each plate 
were counted after 24 hrs. The average CFU was calculated from the duplicate plates 
prepared for each dilution at each time interval. All plates with 30 to 300 CFUs were 
considered measureable, and the CFU per mL for each plate was calculated by taking 
account the dilution factor via the following formula:  
 
CFU/mL = (CFU/100 μL) × dilution factor × 1000, 
 
 
where the average CFU (between 30 to 300 colonies) for every 100 μL of the solution 
spread unto the agar plate is the CFU/100 μL; the dilution factor is the total number of 
unit volume used to make the final solution volume, i.e. Solution A is 10 times more 
dilute than the original stock solution while solution B is 10 times more dilute that 
solution A therefore the solution B should be multiplied by 100; and 1000 is the 
conversion factor from μL to mL.  Multiple stock bacterial solutions were made and 
placed in cryopreservation to run checkerboard assays.  Cryopreservation was 
accomplished by incubating a single colony of bacteria in 2.00 mL of Müeller-Hinton 
broth for a 24-hr period. After incubation, it was added to 20.0 mL Müeller-Hinton broth 
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in a 150 mL Erlenmeyer flask to make a stock solution and was shaken for 2 hr at 200 
rpm at 37
o
C. After 2 hrs, the bacterial solution is dispensed into sterile cryovials with 
glycerol (1:1 ratio).  
To monitor the bacterial growth based on optical density, the original stock 
solution of bacteria was incubated at 37
o
C while shaking at 200 rpm.  The OD600 was 
measured at a 30-minute time interval for a 9-hr period. In addition, the growth plates 
were prepared concomitant with each OD600 measurement at every time point. 
 Based on the growth curve, log phase begins at 2.5 hrs of shaking at 200 rpm at t 
37
o
C. At the log phase, the bacteria grow exponentially at which point a 5.0 × 10
5 
CFU/mL stock is made and added to checkerboard assay with the test samples 
combined with berberine. The growth of the bacteria in the plate after 18-hr incubation 
period is assessed using OD600 measurements. 
2.3.2 Plant material, extract preparation and LC-MS 
 
 Hydrastis canadensis L. (Ranunculaceae) was cultivated in its natural habitat (a 
hardwood forest in Hendersonville, NC, N 35° 24,277’, W 082° 20.993’, 702.4m 
elevation) and harvested in September of 2008.  A voucher specimen was deposited at 
the Herbarium of the University of North Carolina at Chapel Hill (NCU583414) and 
identified by Dr. Alan S. Weakly. 
 The pooled ethanol extracts (50% ethanol: 50% nanopure water) were prepared 
using 100 g of powdered aerial portion (leaves and stems) or roots (including the 
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rhizomes) per 500 mL of solvent (1:5w:v) according to the standard procedures in the 
US dietary supplements industry.90 Plant material was blended with solvent, macerated 
for 24 hrs and filtered under vacuum.  Extracts were stored in amber bottles at room 
temperature. Berberine concentration was determined using liquid chromatography-
mass spectrometry (LC-MS) using a mass spectrometer with electrospray source (LCQ 
Advantage Thermo) coupled to reversed phase HPLC (HP1100; Agilent).  A C-18 column 
(50mm x 2.1 mm, 3 µm particle size, 110 Å pore size, Prevail packing; Grace and 0.5 µm 
precolumn filter, MacMod Analytical) was utilized to characterize the pooled ethanol 
extracts, using 0.2mL/min flow rate and 10 µL injection volume.   The following gradient 
was used to analyze the extracts, where A = 1% acetic acid in nanopure water and B = 
HPLC grade acetonitrile: 100-68% A from 0 to 5 min; 68% A from 5-20 min 0%A from 20 
to 25 min, 100% B from 25 to 40 min.  The detection was conducted in the positive ion 
mode with a scan range of 50-2000 m/z. Capillary temperature was 275 °C, sheath gas 
pressure was 20 (arbitrary units), and spray, capillary, and tube lense voltages were 4.5 
kV, 3 V, and 60 V respectively. 
 A standard of berberine was prepared at a stock concentration of 1 mg/mL in 
methanol.  Calibration curves over a concentration range of 0.005 to 100 µM were 
created using the peak area of the selected berberine ion versus concentration.  The 
ethanol extracts were diluted as necessary in 50:50 ethanol:water to yield berberine 
concentrations within the linear range of the calibration curve.   Berberine was 
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identified in the extracts by fragmentation patterns and retention matching with the 
standards. 
Pre-weighed air-dried leaves of goldenseal were homogenized using a 
commercial coffee grinder (Kitchen Aid). The ground leaves were percolated with 
methanol for at least 24 hr., at which time the solvent was removed and replaced with 
an equivalent volume of methanol. The residue-free methanol extract was collected and 
concentrated in vacuo using a rotary evaporator (Heidolph Laborota 4000 Efficient). The 
methanol extract was re-suspended in 9:1 methanol:water and then partitioned with 
hexane in a separatory funnel. The aqueous methanol layer was separated from the 
non-polar hexane layer and subsequently partitioned with 4:1 ratio of chloroform to 
methanol in water in a separatory funnel. The hexane layer was collected, dried in vacuo 
and was set aside for testing. The chloroform-methanol layer was washed with 1% 
saline solution to remove water-soluble tannins. 
2.3.3 Checkerboard assay with S. aureus NCTC 8325-4 
 
 Extracts were dried under nitrogen and redissolved in Müeller Hinton broth 
containing 10% DMSO and filtered through a 0.45 µm PVDF filter.  Broth microdilution 
MIC assays were performed according to Clinical and Laboratory Standards Institute 
(CLSI) guidelines.91 All extracts were standardized to berberine and tested in 
combination with berberine with a checkerboard assay92  over various concentrations 
ranging from 5 to 300 µg/mL standardized to the mass of berberine within the extract or 
31 
 
fraction. The fractionated chloroform extract (fraction 4 and sub-fraction 2)  did not 
contain berberine and was tested from a range of its highest soluble concentration of 50 
µg/mL to its lowest concentration of 5 µg/mL .   A purified standard of berberine served 
as the positive control.  The assay was performed in triplicate in 96-well plates with 1 x 
105 CFU/mL S. aureus, 2% final DMSO content, and a final well volume of 250 µL.  The 
negative (vehicle control consisted of 2% DMSO in Müeller Hinton broth. MIC values 
were determined at the point at which there was no significant difference between the 
OD600 of the vehicle control and the treatment.  A duplicate 96-well plate was made 
with the varying treatments (berberine, extract, or fraction) without the addiction of 
bacteria and the OD600 was subtracted from the relevant assay wells to minimize 
interference.  FIC values were calculated according to equation 1, where B is the 
compounds, extracts, or fractions tested in combination with A which is berberine.  
MICA is defined as the minimum inhibitory concentration of A alone, and MICB is defined 
as the minimum inhibitory concentration of B alone, and [B] is defined as the MIC of B in 
the presence of A, and [A] is defined as the MIC of A in the presence of B. 
 Fractions 4 and 5 separated from the chloroform aerial extract were tested in 
combination with the chloroform aerial extract to test for synergy within the plant 
fractions.  MIC and FIC values were determined by constructing isobolograms from the 
checkerboard assay. The negative and positive controls were the same as the previously 
stated checkerboard assay methods.
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2.4 Results and discussion 
 
2.4.1 Characterization of S. aureus wild-type NCTC 8325-4 
 
 The goal of this experiment was to characterize a wild-type strain of S. aureus to 
use to test for synergy activity in the checkerboard assay.  By characterizing the 
behavior of S. aureus, optimal treatment of the bacteria could be implemented to 
acquire accurate results.  Through a growth curve, the log and lag phases and the 
relationship between absorbance and colony forming units (CFUs) was determined, 
providing consistent methodology for synergy testing for bioactivity assays. 
A growth curve was constructed by plotting the OD600 (primary y-axis) and 
CFU/mL (secondary y-axis) versus time as shown in Figure 3. The growth curve was 
collected each time a new bacteria stock was prepared and cryopreserved. This allowed 
the specific CFU/mL to be calculated. Thus, further assays were standardized to a 
concentration of 5 x 105 CFU/mL.  A growth curve for each strain of bacteria was 
constructed every six months using the same methodology to confirm the exponential 
growth phase and the relationship between CFU and absorbance. 
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.  
Figure 3. Growth curve for the  wildtype S. aureus (NCTC 8325-4). Log phase was 
determined to be 2.5 hrs to 5.5 hrs. Colony Forming Units (CFUs) were plotted as a 
function of time and correlated to absorbance.  
 
 
The relationship between OD600 and CFU/mL was established by the data 
collected for the growth curve (Figure 3) and a calculation to determine the desired 
OD600 to correspond with 5.0 × 10
5 
CFU/mL using the best fit line for the plot of OD600 
vs. CFU/mL (Figure 4 ). This final diluted stock solution at 5.0 × 10
5 
CFU/mL was then 
dispensed at 50 μL per well in the synergy assay to give 1.0 × 10
5 
CFU/mL at final well 
volume, consistent with CLSI guidelines.11 
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Figure 4.  Calibration curve determining the colony forming unit per milliliter of 
solution (CFU/mL) at an OD600 
 
2.4.2 Detection and quantification of berberine in extracts of Hydrastis canadensis 
 The goal of this experiment was to determine and distinguish the antimicrobial 
compound berberine within the aerial and root portions of the plant, and to determine 
which portion contained more synergists identified via the checkerboard assay. Before 
testing extracts for antimicrobial synergy against the wild-type S. aureus, the quantity of 
berberine within the extract was determined.  It was hypothesized that quantifying the 
level of berberine and standardizing it in the bioassay would allow for characterization 
of each extract as a synergist using the traditional checkerboard assay.  Furthermore, 
the relative abundance of possible synergists to the antimicrobial compound berberine 
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could be evaluated.  This could help further optimize preparation of Hydrastis 
canadensis extracts for commercial applications. 
The quantification of berberine within various extracts allowed testing for 
synergy in Hydrastis canadensis.   A crude ethanol extract of both the root portions and 
aerial portions of the plant were prepared using standard commercial methodology.  
Each extract was then standardized to berberine. The alkaloid berberine (Figure 2) was 
identified in all extracts based on the mass to charge ratio (m/z), CID fragmentation 
patterns and retention times matching with the standard compound (Figure 5).  
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Figure 5. Comparison of base peak LC-MS chromatograms for the berberine, 
hydrastine and canadine in equilmolar concentrations at 1 µM (A) and a 100-fold 
dilution of the ethanolic extract from the pooled aerial portions of H. canadensis. 
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Berberine and two other alkaloids found in Hydrastis canadensis, canadine and 
hydrastine, were identified  from the aerial portion of Hydrastis canadensis by matching 
m/z, retention time, and fragmentation patterns with that of standards (Figure 5).   The 
numbers above the peaks indicate the m/z value of the ion detected, which was 
consistent with M+ for berberine (monoisotopic mass of 336.12 g/mole), and MH+ for 
hydrastine and canadine (monoisotopic masses of 384.14 and 340.15 g/mole, 
respectively).  CID fragments of the M+ ion for berberine (Figure 5C), the MH+ ion for 
hydrastine (Figure 5E), and the MH+ ion for canadine (Figure 5G), corresponded to ions 
in the extract (Figure D, F, and H).  In all other extracts and fractions, alkaloids were 
identified in the same manner. 
 Calculations of the concentration of berberine using the calibration curve of the 
standard showed that the roots contained a higher concentration than the leaves (Table 
1).  The pooled ethanol root/rhizome extract had an average of 2 times more berberine 
(16.6 ± 0.3 mM) than the aerial ethanol extract (8.0 ± 0.1mM) (Table 1).  
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Table 1. Quantity of alkaloids in extracts from the pooled root and rhizome ethanol 
extract, pooled aerial ethanol extract, or crude chloroform aerial extract.  
Concentrations were calculated from calibration curves for standards of each alkaloid 
analyzed with LC-MS in the positive mode. 
 
berberine 
(mM) ± SE 
hydrastine 
(mM) ± SE 
canadine 
(mM) ± SE 
Pooled aerial ethanolic extract 8.0 ± 0.1 2.61 ± 0.05 0.054 ± 0.008 
Pooled root/rhizome ethanolic 
extract 
16.6 ± 0.3 3.79 ± 0.07 0.069 ± 0.011 
Crude Chloroform Extract 7.78 ± 0.60 1.12± 0.12 0.45 ± 0.0040 
 
 
2.4.3 Synergy assessment of both root and aerial of commercially prepared extracts 
  
 The goal of this experiment was to determine which portion of the plant (aerial 
or root) acted more synergistically with berberine to help prepare future commercial 
application of H. canadensis as an herbal supplement.  By characterizing the bacteria 
with the growth curve and quantifying the alkaloid berberine within the different 
samples testing for synergy between the different extracts was able to be performed.  
Extracts with known concentrations of berberine were tested in a checkerboard assay in 
combination with berberine to see if there was an additive or synergistic interaction.   
 As indicated by the FIC value of 0.375 (Table 2) and by the convex shape of the  
 
isobologram (Figure 6) the ethanol aerial extract of H. canadensis synergistically  
 
enhanced the antimicrobial activity of berberine.  Interaction between the roots and  
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berberine was observed to be additive when used in combination in the checkerboard  
 
assay with an FIC value of 0.50 (Table 2). For validation purposes, berberine was tested  
 
in combination with itself (Figure 6), and the effect was additive (FIC of 1.00, linear  
 
isobologram).  The ratio of synergism to the level of berberine was determined to be  
 
much higher in the aerial ethanolic extract. 
  
 
Table 2.  MIC and FIC Values (Indicative of Synergy) for Hydrastis canadensis extracts 
and fractions against Wild-Type S. aureus (NCTC8325-4). 
 
MIC  (μg/mL) FIC Index 
Berberine 150 1.00 
Ethanol Root 150 0.75 
Ethanol Aerial 75 0.375 
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Figure 6. Isobologram indicating inhibition of bacterial growth by H. canadensis 
extracts and added berberine.  Berberine alone was also included in the assay for 
validation and to serve as a positive control for an additive effect.  Extracts were 
dissolved in 2% DMSO in Müeller Hinton broth.  Assays were performed in triplicate in a 
96-well plate with 5 x 105 CFU/mL S. aureus. 
 
 
 The results of this experiment as well as the one performed in section 2.4.2 
provided insight to how commercial preparation of H. canadensis could be improved to 
enhance the antimicrobial of extracts.  The data shows higher berberine content in the 
root portion of the plant with a higher synergistic activity in the aerial portion. 
Therefore, a combination of the two could potentially make effective treatment.   
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2.4.4 Synergism within extracts and fractions of Hydrastis canadensis in synergy-
guided fractionation approach 
 
 The goal of this experiment was to use synergistic activity with berberine as the 
method for fractionation to isolate possible synergist from a large scale chloroform 
extract.  By standardizing the concentration of berberine within each of these extract 
preparations, synergistic activity with berberine could be analyzed between the 
different fractions.  Furthermore, individual fractions tested in combination help to 
direct the fractionation process.  This methodology has the potential to be applied to a 
variety of complex extracts to identify possible synergists for a desired bioactivity. 
 Below is the synergy-guided fractionation schematic for the crude chloroform 
extract of H. canadensis (Figure 7).  The fractionation process and identification of 
synergists were performed by Dr. Hiyas Junio.  During each stages of fractionation a 
modified checkerboard assay was implemented in order to determine synergistic 
activity of each fraction with berberine.  The most synergistically active fractions were 
selected for further fractionation until pure compounds were obtained.  
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Figure 7. Fractionation and synergy testing for the chloroform extract from Hydrastis 
canadensis.  Synergy testing is used to identify extracts and fractions likely to contain 
combinations of compounds that work together. Dr. Hiyas Junio was able to isolate 3 
flavonoids (sideroxylin (1), 8-desmethyl-syderoxylin (2), and 6 desmethylsyderoxylin.112 
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Figure 8. Isobologram indicating inhibition of bacterial growth by fractions 4 and 5 
from the chloroform extract in combination of the crude chloroform extract. Extracts 
were dissolved in 2% DMSO in Müeller Hinton broth.  Assays were performed in 
triplicate in 96-well plate with 5 x 105 CFU/mL S. aureus. 
 
 
 From the isobologram FIC Index values were calculated. With a FIC Index value of  
 
0.32 for fraction 4 and 0.82 for fraction 5 (Table 3) and the concave shape of the  
 
isobologram (Figure 8) fraction 4 was characterized as a synergist when combined with  
 
the chloroform extract and fraction 5 was characterized as being additive in  
 
combination.  In this case there was no standardization to berberine, yet a synergistic  
 
interaction could be observed.  Although not as significant of an effect as shown when  
 
fraction 4 was combined with berberine (Figure 9), it is important to note the possible  
 
applications to other natural products where no active constituents have been  
 
identified.   Also, continuation of this application during the fractionation process would  
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help isolate the bioactive compound (additive effect) and the synergistic compounds  
 
(synergistic effect). Based on this data it was hypothesized that Fraction 4 would most  
 
likely contain compounds responsible for the observed synergistic activity. However,  
 
this approach was not implemented due to berberine being well characterized as the  
 
primary antimicrobial agent found within H. canadensis. 
 
 
Table 3.  MIC and FIC Values (Indicative of Synergy) for Hydrastis canadensis Extracts 
and fractions against Wild-Type S. aureus (NCTC8325-4). 
   
MIC  (μg/mL) FIC Index 
Fraction 4 >150 0.32 
Fraction 5 >150 0.82 
 
 
 Fraction 4 was further fractionated into six subsequent fractions by Dr. Hiyas 
Junio (Figure 7) based on its apparent synergistic activity in combination with the crude 
extract (Figure 8) and berberine (Figure 9).  Each of the subsequent fractions were 
assessed for synergistic activity using the checkerboard assay, and subfraction 2 
exhibited the greatest synergistic activity with an FIC value of 0.03 (Table 4). 
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Figure 9. Isobologram for berberine, the chloroform aerial extract of Hydrastis 
canadensis, the most active fraction from the first stage of separation (aerial fraction 
4), and the most active fraction from the second stage of separation (aerial 
subfraction 2).  All were tested in combination with berberine.  The crude chloroform 
extract and its two fraction synergistically enhanced the antimicrobial activity of 
berberine, as demonstrated by the convex shape of the isobolograms, and the FIC 
values reported. 
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Table 4.  MIC and FIC Values (Indicative of Synergy) for Hydrastis canadensis extracts 
and fractions against Wild-Type S. aureus (NCTC8325-4). 
   
MIC  (μg/mL) FIC Index 
Berberine 150 1.00 
Stage 1   Crude Aerial 100 0.19 
Stage 2   Fraction 4 >50 0.13 
Stage 3  Sub-Fraction 2 >50 0.03 
 
 
When following the synergy-guided fractionation process from crude extract to 
isolated synergist, the level of synergistic activity increased (Table 4).   Fraction 4 (Figure 
9) was the most active of the fractions collected from the first stage of separation from 
this extract.  At its maximal solubility the concentration of was 50 µg/mL, Fraction 4 
(Figure 9) was characterized as a potentiator by having no antimicrobial activity 
observed at this concentration while enhancing the effect of berberine by lowering its 
MIC to 4.7 µg/mL.  Subfraction 2 (Figure 9) was the most active of the fractions collected 
from the second-stage separation and exhibited a maximal solubility concentration of 
50 µg/mL and was characterized as a potentiator by having no antimicrobial activity 
observed at this concentration while enhancing the antimicrobial activity of berberine.  
After further characterization by Dr. Junio of subfraction 2, 3 flavonoids (Figure 6) were 
identified as synergists, 6-desmethyl sideroxylin, sideroxylin, and 8-demethysidroxyln.112  
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2.5 Conclusion 
 
 With the increasing resistance to therapeutic strategies and overall healthcare 
cost S. aureus has acquired as mentioned in the first chapter, it has become more 
important to implement new strategies to address this growing problem. One suggested 
avenue is a multidrug therapy approach using a strategy in which activity of 
antimicrobial compounds is enhanced by other compounds in a synergistic manner.  
Thus, this methodology in identifying synergists in the complexity of a plant extract 
provided a useful tool in discovering compounds that may increase the efficacy of 
presently used treatments.  
 From an economic aspect, roots from Hydrastis canadensis are more commonly 
employed medicinally because of their high alkaloid content compared to the leaves. 
The results do concur the root extract is higher in alkaloid content; however when the 
aerial portions are standardized to berberine the level of synergy in the aerial portion of 
the plant is significantly higher. This indicates that some constituent(s) other than 
berberine in the extract from Hydrastis canadensis aerial portions synergistically 
enhance the antimicrobial effect of berberine.  These constituents were determined to 
be flavonoids acting as potentiators with no observable antimicrobial effect.. 
 Commercially, a combination of root and aerial extracts of Hydrastis canadensis 
could be more beneficial than current preparations seeing as though the findings show  
the aerial portion of the plant have higher levels of synergists while the roots have 
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higher level of alkaloids .  Although, further studies are needed to determine the safety 
and efficacy of such a combination, the data here provides useful information to the 
future cultivation strategies in commercial development.  Through the implementation 
of the aerial portions of the plant, a large portion of the Hydrastis canadensis population 
can be preserved by conserving the plant during harvest.   
 Although the checkerboard assay has been traditionally used to characterize two 
individual components (Drug A and Drug B)  as synergists, antagonists, or additive in 
nature, this study demonstrates that synergy in complex extracts can be identified by 
standardizing a constituent within that extract with a specific biological activity and 
testing it against itself at varying concentrations. In the case of Hydrastis canadensis, the 
aerial ethanolic extract of the plant contains a higher ratio of synergism to berberine 
ratio compared to that of the roots.  Furthermore, by testing for synergism as a guide 
for the fractionation process using the modified checkerboard assay, synergism within 
the plant could be attributed to specific isolated compounds.  
A suggested synergism can also be observed without standardizing a constituent 
found within the extract as seen with Fraction 4 and 5 in combination with the crude 
chloroform extract.  Although berberine was not standardized within this checkerboard 
assay, a comparison of interaction between fractions and the crude extract can be 
useful to identify fractions with a greater synergistic activity. In addition, this 
methodology is useful in determining the relative abundance of synergists in different 
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portions of the plant, which can aid in the commercial application and preparation of 
Hydrastis canadensis. Furthermore, future synergy-guided fractionation processes of 
complex natural products may not have known bioactive compounds, and this approach 
could help facilitate the fractionation process.  Fractions with bioactive compounds 
should behave in a more additive manner with the crude extract whereas synergists 
should have a more synergistic effect with the crude extract.     
In general this study has shown that a synergy-guided fractionation approach 
can be implemented to determine possible antimicrobial agents, in this case berberine, 
within a complex extract and distinguish the antimicrobial agent from synergists 
(flavonoids).  As opposed to bioactivity-guided fractionation, synergy-guided 
fractionation with the crude extract allowed for the identification of an extract 
containing a synergist before the fractionation process was conducted.  Furthermore by 
testing subsequent fractions with the original crude extract, we were able to determine 
which fractions were the most likely candidates to contain synergist.  The process serves 
as a useful tool to identify synergist along with antimicrobial compounds from a 
complex plant extract. 
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CHAPTER III 
MECHANISM OF ACTION OF SYNERGISTS FROM HYDRASTIS CANADENSIS 
 
3.1 Abstract 
 
Rational:  The goals of this study were to characterize the mode of action by which 
complex aerial and root extracts of Hydrastis canadensis act to enhance the 
antimicrobial effect of berberine against various strains of S. aureus, and to determine 
whether synergists isolated from Hydrastis canadensis act as multi-drug resistance 
(MDR) pump inhibitors. 
Methods: S. aureus strains NCTC-8325-4 (wildtype), K1902 (NorA knockout), K2703 
(NorA complemented) were used to determine efflux pump inhibition for chloroform 
aerial extracts of Hydrastis canadensis through confocal microscopy.  K1902 and K2703 
were characterized via a growth curve and implemented in a fluorescence-based 
ethidium bromide efflux assay along with NCTC-8325-4 to evaluate the efflux pump 
inhibitory activity of complex extracts and isolated synergists from Hydrastis canadensis. 
Results and Discussion: The aerial extracts of Hydrastis canadensis had more 
pronounced efflux pump inhibitory activity against wildtype S. aureus than did root 
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extracts based both on confocal microscopy measurements and the ethidium-bromide 
efflux assay.  The flavonoids 8-desmethyl-sideroxylin, 6-desmethyl-sideroxylin and 
sideroxylin isolated from sub-fraction 2 in Figure 20 also inhibited the efflux of ethidium 
bromide by wildtype S. aureus, suggesting efflux pump inhibitory activity for these 
compounds.  Consistent with this conclusion, no significant difference between treated 
and control cells was observed for efflux pump (NorA) knockout S. aureus.  Of the 
flavonoids tested, 6-desmethylsideroxylin had the most pronounced efflux pump 
inhibitory activity. 
Conclusions:  Extracts from Hydrastis canadensis contain flavonoids which inhibit efflux 
pumps in S. aureus.   The aerial portions of the plant appear to have highest efflux pump 
inhibitory activity, likely due to the presence of higher concentration of flavonoids.   
3.2.  Introduction 
 
3.2.1 Multi-Drug-Resistant pumps in S. aureus 
 
 The number of antibiotics to which S. aureus has developed a resistance to over 
the past ten years has risen considerably.  As a result, many antimicrobial compounds 
have been rendered ineffective.  A major mechanism by which bacteria become 
resistant to antibiotics is an up-regulation in the number of multi-drug resistant efflux 
pumps (also referred to as MDR pumps).93 Efflux pumps work through actively exporting 
an antimicrobial agent from the cell via efflux before the antimicrobial agent reaches 
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high concentrations.94 The multidrug efflux system in S. aureus consists of transporter 
proteins which export a broad range of structurally unrelated compounds.95  
 The gene sequence of S. aureus N315, which is comparable to the NCTC 8325-4 
strain, consists of a 2.81 Mb genome with a total of 212 transporters.96  There have 
been 20 of these 212 transporters identified as multidrug efflux pumps with high levels 
of genomic conservation in the N-terminal ends relative to the C-terminal.   Thus, it is 
hypothesized that the N-terminal  end is involved in activation while the C-terminal is 
important for substrate specificity19.   
 The NorA transporter, a MDR pump, is found in clinical isolates of S. aureus able 
to efflux a range of structurally different compounds.97 It is considered the major 
chromosomal MDR pump in this species of bacteria.98  In S. aureus, NorA enhances 
resistance to azoles, acriflavin, fluoroquinolones, puromycin, chloramphenicol, ethidium 
bromide, and other quaternary amine compounds including the alkaloid berberine.  The 
NorA pump itself clusters, forming a total of 12 transmembrane proteins, which rely on 
the proton motive of force in order to efflux antimicrobial agents outside the cell. By 
taking in protons into the bacterial cell using a proton gradient, the efflux pumps are 
able to export antimicrobial substrates outside the cell before they reach high enough 
concentrations to kill the cells.21  
 One of the major pioneers in evaluating efflux pump inhibition as a mechanism 
of increasing the efficacy of antimicrobial agents was Frank R. Stermitz.  In 2001, his lab 
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was able to isolate two efflux pump inhibitors that were active against S. aureus., 
5’methoxyhydnocarpin D from leaves of Berberis trifoliolata and phenphorbide a from 
Berberis fendleri. These efflux pump inhibitors enhance the antimicrobial effect of 
berberine, an antimicrobial agent found within the plants.105 It was these research 
findings that lead to the investigation of H. canadensis and its purified flavonoids a 
possible source of efflux pump inhibition.  
3.2.2 Hydrastis canadensis as a possible efflux pump inhibitor 
 
 Methanol extracts of aerial portions of Hydrastis canadensis have been shown to 
achieve MIC (minimum inhibitory concentrations) of 40 and 160 µg/mL against C. 
glabrata and C. albicans.  Furthermore, the methanol extract of this plant was shown to 
be effective against azole-sensitve clinical isolates of C. glabrata (BPY112 and BPY126) 
which over expresses multidrug efflux pumps Cg,CDR1, CgCDR2, and CgSNQ2.  Two 
strains of azole-resistant C. albicans, over expressing CDR1 and CDR2 were also inhibited 
by the extract of Hydrastis canadensis.99 The data from this paper suggest that 
secondary metabolites in the aerial portion of Hydrastis canadensis may be synergistic 
by acting as  MDR pump inhibitors.100 
3.2.3 Hydrastis canadensis an inhibitor of MDR pumps in the liver  
 
 Berberine has been shown to be an effective compound to have an effect at 
lowering cholesterol in blood plasma.  High cholesterol is a primary cause of heart 
disease and can significantly increase blood pressure. Typically, these chronic illnesses 
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are treated with a class of compounds called statins (atorvastatin (Lipitor®) and lovostatin 
(Mevacor®, Altocor®, Altoprev®). Where presently used statins work by inhibiting HMG-
CoA reductase which is involved in the biosynthesis of cholesterol; berberine has been 
shown to act in a different manner. Berberine up-regulates the mRNA encoding hepatic 
low-density lipoprotein receptor (LDLR), which regulates the uptake of plasma low-
density lipoproteins (LDL) control into the liver where it is oxidized into bile acids.101 
 The high content of berberine found in Hydrastis canadensis extracts lead to the 
testing of root extracts standardized to berberine for LDL levels in the blood and 
comparing the results to berberine alone at the same concentrations.  It was shown the 
root extract of H. canadensis was more effective at up-regulating LDLR in HepG2 when 
compared to pure berberine at the same concentration.102    This led the Abidi group to 
explore the mechanism of action to obtain this observed activity.  
 When treated with Hydrastis canadensis extracts obtained from four different 
lots, the level of LDLR mRNA expression was elevated when compared to berberine alone at 
the same levels of concentrations standardized to berberine.  Verification of activity was 
confirmed by a Northern blot analyses and quantification using real time PCR of the RNA 
harvested from the treated HepG2.  It was hypothesized the elevation of the LDLR mRNA 
resulted from mRNA stabilization because the LDLR promoter activity was unaffected by 
treatment.  In a time course study, the level of LDLR mRNA increased at a faster rate when 
treated with the plant extract compared to purified berberine.  Furthermore, at the same 
concentrations of berberine in pure berberine alone and in the extract, the treatment with 
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extract caused a ~13 fold increase in accumulation of berberine within the HepG2 cells. It 
was also noted berberine is actively effluxed from bacterial cells by multidrug resistance 
pumps and therefore the group postulated the multi-drug transporter 1 (MDR1) pgp-170 in 
HepG2 cells plays a role in the accumulation of berberine within the cell.103 
To test for the MDR1 inhibitory effects of Hydrastis canadensis a known substrate 
for MDR 1 that fluoresces, DiOC2, was monitored with verapamil serving as the positive 
control.  The results showed an increase in the uptake of DiOC2 when treated with the plant 
extract compared to the vehicle control and the treatment was comparable with the 
positive control verapamil.  The group hypothesized minor constituents in the extract act as 
natural antagonists for the MDR1 transporter leading to the increased uptake of berberine 
in HepG2 causing an overall increase in LDLR mRNA expression.104 
It has also been well established S. aureus and other bacteria have MDR pumps 
directly responsible for the efflux of the alkaloid berberine outside the cell.105  Paired with 
the enhancement of the antimicrobial effect of berberine shown in chapter II and the 
results from the Albidi group with the increase uptake of berberine in HepG2 cells it was 
hypothesized the unknown minor constituents in Hydrastis canadensis that were postulated 
to be MDR 1 inhibitors could be the flavonoids isolated and identified as synergists in the 
previous chapter.  Furthermore, we hypothesized the aerial portion of the plant would have 
a greater efflux inhibitory activity based on the higher concentrations of flavonoids 
determined by Dr. Junio in the Cech lab.106 The goal of the experiment described in this 
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chapter was to test these hypotheses by measuring the efflux pump inhibitory activity of H. 
canadensis extracts and their purified flavonoids.  
3.2.4 Ethidium bromide based assay for efflux pump inhibition 
 
 A different approach for identifying possible efflux pump inhibitors than 
measuring MIC values with or without treatment (EPIs) has been to use ethidium 
bromide, a fluorescent dye, which is a substrate for most MDR efflux pumps in S. 
aureus.   By measuring intracellular fluorescence readings of the dye both with and 
without the potential efflux pump inhibitor one can determine the net effect of the 
candidate compound. Efflux of ethidium bromide via the NorA pump has been observed 
in S. aureus using confocal microscopy.107  Ethidium bromide fluoresces a bright red 
when intercolating to the DNA in S. aureus.  By loading bacterial cells with ethidium 
bromide, a decrease in fluorescence can be observed over time.  This inhibition activity 
can be quantified by measuring the fluorescence directly using a spectrophotometer.  
3.3 Experimental 
3.3.1 Confocal microscopy to measure efflux pump inhibition 
 
The growth curve and CFU/mL of SA-K1758 (norA deleted) and SA-K2708 (norA 
complemented) were measured using the same protocol described in Section 2.2.1. The 
confocal microscopy method was used to visualize efflux of ethidium bromide outside 
the cell using a NorA knockout strain of S. aureus (SA-K1758) and a NorA complemented 
strain (SA-K2378).  The bacteria were grown to an OD600 of 0.84 in Müeller-Hinton 
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broth.  Ethidium bromide (25 µM) and the known efflux pump inhibitor carbonyl 
cyanide m-chlorophenylhydrazone108 (CCCP, 100 µM final concentration) were added, 
and the bacteria were incubated at 20°C with agitation (200 RPM) for 20 minutes.  This 
solution was diluted to OD600 = 0.36 with broth containing ethidium bromide and CCCP 
at 25 µM and 100 µM.  Aliquots (1 mL) were centrifuged at 20°C for 5 minutes at 13,000 
x g in a Spectrafuge 24D centrifuge (Labnet).  The pellets were stored on ice for <1 hr.  
Prior to measurement, the pellets were thawed for 5 minutes and resuspended in 1  mL 
of fresh broth containing 10% DMSO and treatment of plant extract at 1 mg/mL or CCCP 
100 µM.  The solution was placed on a slide with a cover slip.   Each sample was 
observed  at  t = 1 minute and t = 5 minutes using a confocal microscope (Olympus 
1X81/Confocal Laser Scanning Microscope with Olumpus Fluoview500 software, a 
HeNe-Green (543 nm) excitation laser and an, Olympus PlanApo 60x11.40 oil objective). 
Measurements were carried out using three strains of S. aureus (NCTC SA-8325-4, 
K1758, SA-K2702). 
3.3.2 Quantization of relative fluorescence 
 
The efflux pump inhibition assay was conducted using a previously published 
method.109 Wild-type S. aureus (NCTC 8325-4) and an isogenic NorA deletion mutant 
(K1758 NorA deleted)were grown to OD600 = 0.74 in Müeller-Hinton broth. Ethidium 
bromide (25 μM) and carbonyl cyanide m-chlorophenylhydrazone (CCCP, 100 μM) were 
added, and the bacteria were incubated at 20 °C with agitation (300 RPM) for 20 min. 
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This solution was diluted to OD600 = 0.40 with broth containing ethidium bromide and 
CCCP at 25 μM and 100 μM, respectively. Aliquots (1 mL) of this solution were 
centrifuged at 20 °C for 5 min at 13,000 × g in a Spectrafuge 24D centrifuge (Labnet). 
The pellets were stored on ice for <1 hr. Prior to measurement, the pellets were thawed 
for 5 min and 1 mL of fresh broth containing DMSO (10% final assay concentration) and 
treatments (CCCP, extract or pure compound) were added to achieve a final 
concentration of 50 µg/mL. Fluorescence of these solutions was measured every second 
for 300 s with λex = 530 nm, λemiss = 600 nm, and slit widths of 5 mm. 
3.4 Results and discussion 
3.4.1 NorA knockout (SA-K1758) and NorA complemented (SA-K2708) growth curve 
 
 The goal was to characterize the mutant strains of S. aureus SA-K1758 and SA-
K2708 to optimize growing conditions and implementation in following experiments.  By 
determining the log and lag phase of the different strains the growth time for each 
bacteria was determined for the subsequent efflux assays.   
A growth curve was constructed by plotting the OD600 (primary y-axis) and 
CFU/mL (secondary y-axis) versus time as shown in Figure 10. The growth curve was 
collected each time a new bacteria stock was prepared and cryopreserved. This allowed 
the specific CFU/mL to be calculated. Thus, further assays were standardized to a 
concentration of 5 x 105 CFU/mL.  A growth curve for each strain of bacteria was 
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constructed every six months using the same methodology to confirm the log growth 
phase and the relationship between CFU/mL and absorbance. 
 
 
Figure 10. Growth curve for the NorA knockout S. aureus (SA-K1758). Log phase was 
determined to be 3.5 hrs to 6.5 hrs. Colony Forming Units (CFUs) were plotted as a 
function of time and correlated to absorbance.  
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Figure 11.  Calibration curve determining the colony forming unit per milliliter of 
solution (CFU/mL) at an OD600 for SA-K1758 
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Figure 12. Growth curve for the NorA complemented S. aureus (SA-K2708). Log phase 
was determined to be 2.5 hrs to 5.5 hrs. Colony Forming Units (CFUs) were plotted as a 
function of time and correlated to absorbance.  
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0.00E+00 
5.00E+06 
1.00E+07 
1.50E+07 
2.00E+07 
2.50E+07 
3.00E+07 
3.50E+07 
4.00E+07 
4.50E+07 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
0 2 4 6 8 
A
b
so
rb
an
ce
 
Time (h) 
Growth Curve for NorA complemented (SA-K2708) 
CFUs/mL 
Absorbance 
62 
 
 
Figure 13.  Calibration curve determining the colony forming unit per milliliter of 
solution (CFU/mL) at an OD600 for SA-K1758 
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3.4.2 Confocal microscopy with mutant strains of Staphylococcus aureus 
 
 The goal of this experiment was to determine if various extracts from Hydrastis 
canadensis inhibited the efflux of ethidium bromide within different strains of 
y = 4.27E+07x - 3.57E+06 
R² = 9.92E-01 
0.00E+00 
5.00E+06 
1.00E+07 
1.50E+07 
2.00E+07 
2.50E+07 
3.00E+07 
3.50E+07 
4.00E+07 
0 0.2 0.4 0.6 0.8 1 
C
FU
/m
L 
Absorbance 
Absorbance Vs. CFU 
63 
 
Staphylococcus aurues. By loading bacteria with ethidium bromide and suspending them 
with or without treatment, efflux could be observed directly using a confocal 
microscope.  The NorA knockout strain (SA-K1758) served as our reference control and 
mimicked NorA inhibition by having the gene encoded for NorA deleted. From one 
minute after suspension to five minutes after suspension the observed fluorescence was 
expected not to change.  The rationale behind starting the observation of fluorescence 
after one minute was the this was the time necessary to prepare a slide for analysis on 
the confocal microscope.  
The NorA complemented strain (SA-K2708) was assessed to determine if a NorA 
inhibitor was present upon treatment. By observing the fluorescence over time, 
inhibition was observed through comparison with the positive control CCCP. The level of 
fluorescence observed corresponded to the amount of ethidium bromide within the cell 
intercolating with the bacterial DNA.  Because ethidium bromide diffuses into the cells 
and is actively transported out by the NorA efflux pump, if there was a high relative 
fluorescence over time, then it was concluded there was little efflux of ethidium 
bromide outside the cell via the NorA pumps.  If there was a low to no observable 
relative fluorescence over time it was concluded the bacteria effluxed the majority of 
ethidium bromide outside the cells via the NorA pumps.  If fluorescence was retained in 
the NorA complemented strain in response to treatment with the extract, then it was 
concluded there was a NorA pump inhibitor (or other related efflux pump inhibitor) 
present.   
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Figure 14. Confocal microscopy image of NorA knockout S. aureus (SA-K1758) after 
one minute and 5 minutes suspended in MH broth. 
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 The two images of the NorA knockout strain show that the level of red 
fluorescence observed in the bacterial cells changes very little from one to five minutes. 
The slight change could be attributed to passive diffision of ethidium bromide outside 
the cell or other MDR pumps besides the NorA pump that may exist in the knockout 
strain. Nevertheless, using SA-K1758 (NorA knockout) as a standard to compare to, if 
treatment of Staphylococcus strains with the NorA pump expressed mimic the relative 
fluoresence as shown in Figures 14 it was hypothesized the NorA efflux pumps are 
unable to efflux ethidium bromide outside the cell as a result of inhibition. 
   The knockout strain (SA-1758) was tested with carbonyl cynate m-chloro-
phenylhydrazone, CCCP (positive control), to determine any effects of fluorescence it 
may have over the four minute time period (Figures 15). 
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Figure 15. NorA knockout strain (SA-K1758) after one minute and five minutes 
suspended in broth containing 100 µM carbonyl cyanide m-chloro-phenylhydrazone, 
the control efflux pump inhibitor.  
 
t = 1 min. 
t = 5 min. 
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When the knockout strain was treated with the positive control CCCP at a 
concentration of 100 µM the level of fluorescence was not significantly different 
between 1-5 minutes. However, it was noted a slight increased in fluoresent signal after 
the five minute period.  Observing less fluorescent cells in Figure 15 after one minute 
compared to the five minute time period  under treatment of the positive control 
suggested other MDR (NorB, NorC, SepA) pumps produced by S. aureus could have been 
inhibited through the disruption of the proton motive force. Another possible 
explanation is the bacteria’s tendency to migrate out of the camera lens during the 
course of the 4 minute interval.  This could be a possibity seeing as though the intensity 
of the fluoresence appears not to decrease. 
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Figure 16. NorA knockout strain (SA-K1758) after one minute and 5 minutes 
suspended in broth and 1mg/mL aerial ethanolic extract of Hydrastis candensis.  
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When the knockout strain was treated with the aerial ethanolic extract of 
Hydrastis canadensis there was no observable change in fluorescense between one and 
five minutes of being resuspended (Figure 16).  This confimed the extract itself had no 
affect on the fluorescent properties of the ethidium bromide being exported from the 
cells without the NorA pump. Thus, any retention of fluorescence using the 
complemented NorA strain (SA-K2708) would not have resulted in the inherent 
fluorescent properties of the extract, but would have resulted from the inhibition of the 
NorA pump. 
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Figure 17. NorA complemented strain (SA-K2708) after one minute and five minutes 
suspended in  MH broth.  
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 The confocal images of the NorA complemented strain after suspension using 
broth (vehicle control) showed no observable fluorescence of ethidium bromide at t = 1 
minute or t = 5 minutes (Figure 17).  Seeing no fluorescence suggested the no (or very 
little) ethidium bromide was retained in the cells.  It was concluded the increased 
production of the NorA pump, for which ethidium bromide is a substrate, effluxed the 
ethidium bromide outside the cell within the first minute of suspension with broth. 
Upon repitition, including increased concentration of bacteria, no change in results were 
observed.     
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Figure 18. NorA  complemented strain (SA-K2708) after one minute and five minutes 
suspended in broth containing 100 µM carbonyl cyanide m-chloro-phenylhydrazone 
(CCCP). 
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 When the NorA complemented (SA-K2708) was treated with the positive control 
CCCP, the level of fluorescence was retained after one minute (Figure 18) fluorescence 
of the ethidium bromide within the cell was observed using the confocal microscope.  
Although the fluorescence appeared to decrease slightly after five minutes, enough 
ethidium bromide was retained inside the bacteria cells to observe fluorescence.  This 
suggested that CCCP inhibited the efflux of ethidium bromide outside the cells by 
preventing the function of the NorA efflux pumps, which is consistent with the 
published activity of CCCP as a compound that disrupts the proton motive force.110 
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Figure 19. NorA  complemented strain (SA-K2708) after one minute resuspended in 
broth in broth and 1 mg/mL aerial ethanolic extract of Hydrastis candensis. Image was 
taken using confocal microscope. 
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When the NorA complemented (SA-K2708) was treated with the aerial ethanol 
extract of Hydrastis canadensis, the level of fluorescence measured after one minute 
was significant enough to be observed (Figure 19).  Although the fluorescence appeared 
to decrease slightly after five minutes, enough ethidium bromide was retained inside 
the bacteria cells to observe fluorescence. It was concluded the plant extract inhibited 
the efflux of ethidium bromide outside the cell because the retention of fluorescence 
compared to the vehicle control was significantly higher. 
Through comparing the images of the knockout strain and the complemented 
strain, inhibition of ethidium bromide efflux was confirmed.  In the study with SA-1758 
(NorA knockout) there was no change in fluorescence upon treatment with the plant 
extract when compared to the vehicle and positive controls; however, the NorA 
complemented strain (SA-2708) showed a significant retention in fluorescence over the 
total time of 5 minutes when treated with the plant extract and CCCP compared to 
vehicle control, which showed no fluorescence.    
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3.4.3  Quantification of efflux inhibition 
 
 The goal of this experiment was to quantify the inhibition of NorA efflux pumps 
by H. canadensis extracts and flavonoids by measuring the fluorescence over time with 
cells loaded with ethidium bromide.  Using this technique, we sought to determine 
whether root or aerial H. canadensis extracts were more effective at inhibiting efflux, 
and to also determine the mode of action for synergists isolated from H. canadensis.  
We tested the hypothesis, based on previous literature111, that H. canadensis flavonoids 
(Figure 20) inhibit the function of the NorA MDR pump.  Efflux pump inhibitory activity 
would explain the observed synergism with the antimicrobial alkaloid berberine, 
reported in Chapter II and elsewhere.112 113 
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Figure 20.  Synergists isolated from H. canadensis following the synergy-guided 
fractionation process (Figure 6) were determined to be the flavonoids sideroxylin (1), 
8-desmethyl-sideroxylin (2), and 6-desmethyl-sideroxylin (3).114 
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Figure 21. Percent fluorescence over time for S. aureus (NCTC 8325-4) loaded with 
ethidium bromide and treated with various extracts and controls. Treatments included 
the known efflux pump inhibitor CCCP (positive control), and extracts from the roots 
and aerial portions of H. canadensis. All extracts and CCCP were dissolved in Müeller 
Hinton broth containing 2% DMSO. Data points represent the average of three separate 
experiments (using 3 different pellets of S. aureus). Error bars are +/− standard error.113 
  
 
An ethanol extract prepared from aerial portions H. canadensis (as described in 
Section 2.3.2) was shown to inhibit efflux of ethidium bromide from wild-type S. aureus 
(Figure 21), but not for the knockout strain (Figure 22).  For wild-type S. aureus, the 
percent of ethidium bromide fluorescence after 5 minutes compared to the initial 
reading for bacteria in broth alone was 66.7 % ± 5.5 % for the root extract (50 μg/mL),  
79.2 % ± 1.2 % for the aerial extract (50 μg/mL), and 84.73 %  ± 1.29 % for the positive 
control (CCCP at 20 μg/mL).  The results for the CCCP and the aerial extract were 
significantly different from that of the negative control (ethidium bromide loaded 
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bacteria in Müeller Hinton broth with 2% DMSO), with p values of 0.002 and 0.02, 
respectively.  There was no significant difference in % fluorescence between the root 
extract and the negative control after 3 minutes.  For the norA deleted S. aureus, no 
significant inhibition of ethidium bromide efflux was observed for any of the treatments 
(H. canadensis aerial extract, H. canadensis root extract, or CCCP) after 5 min (Figure 22).  
This suggested the NorA MDR inhibitors were present in the aerial portions of the plant 
but not the roots.  These findings are consistent with the greater synergistic activity 
observed for the aerial extract, as described in Chapter II. 
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.  
Figure 22. Percent fluorescence over time for the norA-deleted (SA-K1758). Conditions 
were the same as described for Figure 21. 
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Figure 23. Percent fluorescence over time for the three flavonoids from Hydrastis 
canadensis inhibit the NorA efflux pump of S. aureus (NCTC-8325-4) (A) and the NorA 
deleted (SA-1758) (B) . Treatments included the known efflux pump inhibitor CCCP 
(positive control). The flavonoids were dissolved in Müeller Hinton broth containing 2% 
DMSO. Data points represent the average of three separate experiments (using 3 
different pellets of S. aureus). Error bars are +/− standard error.112 
 
 
 The results from the ethidium bromide efflux assay with the flavonoids 
illustrated in  Figure 23 with wild-type S. aureus (NCTC-8325-4) showed  the positive 
control carbonyl cyanide m-chlorophenylhydrazone (CCCP) and the three flavonoids 
retained higher levels of fluorescence in relation to the vehicle control after 5 minutes.  
82 
 
The vehicle control only retained 50% relative fluorescence where as the positive 
control (CCCP) retained 92% relative fluorescence.  Although all three flavonoids 
significantly inhibited efflux of ethidium bromide (Figure 23), they had differing 
potencies. Of the flavonoids, 8-desmethyl-sideroxylin retained the highest relative 
fluorescence after 5 minutes with a value of 90% followed by its isomer 6-desmethyl-
sideroxylin (88%), and sideroxylin showed partial NorA inhibition (70%) (Figure 23).  
Overall, these findings suggest that the flavonoids isolated from the synergy-guided 
fractionation process are NorA efflux pump inhibitors.  This hypothesis was verified with 
the knockout (SA-K1758) efflux assay (Figure 23B), where neither the flavonoids nor the 
positive control showed any statistically significant influence on ethidium bromide efflux 
after 5 min.   
3.5 Conclusion 
 
 Through implementing various mutant strains of S. aureus, a possible mechanism 
of action in which extracts prepared from Hydrastis canadensis enhance the 
antimicrobial effect of berberine was determined. By characterizing each strain of 
bacteria to maintain consistent growth conditions, a direct comparison of the results 
amongst the efflux pump inhibition assays could be preformed. Using a fluorescent 
substrate for the NorA efflux pump a qualitative observation of the efflux of both the 
knockout (SA-1758) and complemented (SA-2708) strains was observed under different 
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treatments.  By directly comparing these two strains, activity specifically related to the 
NorA efflux pump can be determined.   
 By complementing the synergy-guided fractionation process with NorA efflux 
pump inhibition with the wildtype S. aureus (NCTC-8325-4) we were able to determine 
the synergistic flavonoids isolated from the aerial portion of Hydrastis canadensis acted 
as NorA efflux pump inhibitors. Through measuring the relative fluorescence of 
ethidium bromide over time a quantification of activity for both crude extracts and 
specific compounds can be determined.  By comparing the relative fluorescence to that 
of the knockout strain (SA-1758) verification of the flavonoids’ bioactivity could be 
confirmed as a NorA efflux pump inhibitor. 
A broader application of the results is the observation the aerial extracts of 
Hydrastis canadensis appear to be more effective at inhibiting the NorA pump 
compared to the root extract at the same concentrations.  Although there is a higher 
alkaloid antimicrobial content in the roots (Chapter II) the increased efflux inhibition in 
the aerial portion of the plant the implementation of sustainable aerial extracts could be 
of more use in the treatment of infection. This could facilitate commercial application of 
extracts prepared from H canadensis and the optimization of a combination of aerial 
and root extracts for total antimicrobial activity of an commercially available therapeutic 
agent prepared from Hydrastis canadensis may be worth pursuing. 
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CHAPTER IV 
 A NEW METHOD TO IDENTIFY NATURAL PRODUCT QUORUM QUENCHERS:  MASS  
 
SPECTROMETRY-BASED MEASUREMENTS OF AUTOINDUCING PEPTIDE PRODUCTION 
 
 
4.1  Abstract 
 
Rationale:  The objectives for these experiments where to directly quantify and 
optimize the production of autoinducing peptide-I (AIP I) from a clinical strain of MRSA 
(AH1293), develop a methodology to observe the inhibition of AIP I (quorum quenching) 
in a 96-well plate assay, and to utilize a bioactivity-guided fractionation approach to 
identify AIP I inhibitors (quorum quenchers) from natural products. 
Methods:  Methicillin- resistant S. aureus (MRSA, AH1263) was grown over a 48 hour 
period and AIP I production was assessed using LC-MS.  Complex extracts of Hydrastis 
canadensis and a Penicillium fungus were fractionated using HPLC into 96-well plates 
and putative quorum quenchers identified.  A large scale extraction of Hydrastis 
canadensis was fractionated based on its bioactivity as a quorum quencher to identify 
possible AIP inhibitors from the plant. 
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Results and Discussion:  It was determined that AIP could be identified in the 
supernatant of filtered bacterial cells using high resolution mass spectrometry (HRMS).  
In a time course study, it was also determined 20 hours is the optimal growing period 
under aeration for this MRSA strain, producing concentration of 27.6 ± 0.25 µM AIP I.  
Quorum quenching could be observed in a HPLC separation of complex extracts into a 
96-well plate for a Penicillium fungus.  The wells where inhibition was observed 
corresponded to those containing anthraquinones known to be inhibitors of the Agr 
 pathway.  Hydrastis canadensis was also shown to be a quorum quencher and the 
constituents responsible were narrowed down to specific fractions using bioactivity-
guided fractionation. 
Conclusion: Autoinducing peptides can be identified in the supernatant of filtered MRSA 
(AH1263) cells using UPLC-high resolution mass spectrometry. The Agr system is 
sensitive enough to use a 96-well plate assay to observe the inhibition of AIP I and 
probable constituents as quorum quenchers from complex natural products.  Detection 
of AIP via mass spectrometry provides a more direct method for in the identification of 
possible quorum quenchers compared to fluorescent methods that have previously 
been used.  
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4.2 Introduction 
 
 Presently, S. aureus is one of the leading causes of hospital acquired infections, 
with the fraction of these caused by MRSA increasing each year. In fact, S. aureus is the 
primary source of hospital-acquired infections in sites in which surgery was performed 
and respiratory tract infections, and second leading cause for nosocomial pneumonia, 
and cardiovascular infections.115 In 2005 alone, MRSA related infections numbered over 
100,000 and were responsible for over 18,000 deaths.116  Recently, more virulent strains 
of MRSA have even spread to the community, called community acquired (CA) MRSA.117   
A major reason for the hypervirulence of the S. aureus strains that cause 
community acquired MRSA is that they have a highly active quorum sensing system.118  
The quorum-sensing system in S. aureus, also called the accessory gene regulator or 
“Agr” system, is a cell density dependent regulatory system that controls the production 
of many host-damaging agents or “virulence factors”.   The Agr quorum sensing system 
consists of four genes, AgrD is the precursor for the Agr system activator autoinducing 
peptide (AIP), AgrA, AgrB, and AgrC are transmembrane proteins responsible for the 
detection, transportation, and activation of the autoinducing peptide Figure 24.119    This 
system has a positive reinforcement aspect meaning as the concentration of AIP 
increases, the pathway is up-regulated in an exponential manner. This system becomes 
activated when the autoinducing peptide (AIP I) binds to the transmembrane AgrC 
protein, which further increases AIP production, and eventually stimulates the 
production of toxin production as well as virulence factors leading to pathogenesis. A 
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principal concern of MRSA infections is the toxin production causing the negative side 
effects of inflammation, fever, tissue necrosis, and fatigue.  Toxin production itself is a 
direct result of the activation of the P2 and P3 promoters that lead to RNAIII production 
in the Agr quorum-sensing pathway.   
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Figure 24. The Agr system consists of four genes, agr ABCD.  The AgrD is the precursor 
to AIP I, and upon binding to the AgrB it forms a marcrocyclic thiolactone (AIP I) and is 
transferred through the cytoplasmic membrane.  AIP I then binds to the AgrC protein, 
causing the phosphorylation of the AgrA, resulting in the activation of both the P2 or P3 
promoter.  The P2 promoter activates the Agr system by turning on the AgrABCD genes, 
while the P3 promoter activates various responses in the bacteria, including the 
production of virulence factors.120 
 
Detection and elucidation of autoinducing peptides has primarily been 
accomplished through bioluminescence assays using the lux reporter gene.121  In these 
bioluminescence is a result of the activation of the P3 promoter and production of 
RNAIII.  The RNAII is tagged with a Lux reporter to indicate its production.   Any 
disruption to the Agr quorum pathway as a response to treatment would lead to a 
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decrease in RNA III production and thus bioluminescence.  Therefore, quorum 
quenching is determined by a decrease in relative bioluminescence compared to a 
vehicle control.122 This approach inherently does not enable absolute quantification and 
does not directly measure AIP I production, rather it measures a downstream effect of 
the Agr system. Furthermore, there are cases where fluorescence based assays yield 
false results due to fluorescence quenching, particularly in complex extracts such as 
those under investigation in this study.  For these reasons, a primary objective of this 
experiment is to develop a new assay that directly measures AIP I, a direct product of 
the Agr system, and to modify it to be compatible with a 96-well plate assay to test 
fractionated extracts as shown in the schematic of Figure 25. 
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Figure 25.  Schematic showing the detection of AIP I in 96 well plate format.  
The extract is fractionated and analyzed on the mass spectrometer.  The plate is 
dried and resuspended  with MRSA (AH1263), grown under aeration (20 hrs), 
filtered and the culture supernatant analyzed using mass spectrometry to 
determine the AIP I production. 
 
4.3. Methods 
4.3.1 Detection and quantification of AIP I in MRSA (AH1263) in a time-course study  
 
For the time course study, a 24 hr culture of MRSA (USA 300 strain AH1263) was 
diluted 1:100 in tryptic soy broth and grown with shaking for 48 hrs.  An aliquot was 
removed every hour, the OD600  was recorded , and the culture was filtered through a 
0.2 µM membrane and analyzed using LCMS. 
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Samples were analyzed utilizing an LTQ Orbitrap XL mass spectrometer 
with electrospray ionization source (Thermo, San Jose, CA) coupled to an Acquity UHPLC 
HSS T3 (Waters, Milford, MA). A C18 column (Acquity BEH, 2.1 mm × 50 mm, packing) 
was used. Flow rate was 0.25 mL/min, and injection volume was 3 µL. Samples 
were eluted at 0.25 mL/min using a two-step gradient from 80:20 to 40:60 
water:acetonitrile (both containing 0.1% formic acid) from 0 to 5 min, then from 40:60 
to 80:20 from 5 to 5.5 min. The Orbitrap was operated over a scan range of m/z 300 to 
2000, with resolving power of 30,000. MS–MS was conducted in data dependent 
scanning mode, using a collision induced dissociation (CID) activation energy of 35%. 
Instrument parameters were as follows, tube lens voltage, 100 V, source voltage, 4.50 
kV, source current, 100.00 µA, and heated capillary voltage, 20 V. The AIP I 
concentration was calculated based on a calibration curve generated as area of the 
relevant selected ion peak versus concentration. A mass of 961.3794 ± 0.0048 (calcd 
accurate mass for the [M+H]+ ion of AIP-I, ±5 ppm) was set for the selected ion 
chromatogram, and AIP I concentrations were calculated using the slope of the best-fit 
line of this calibration curve, as determined with linear regression analysis. This 5 ppm 
window was chosen to reduce interface from isobaric matrix components. 
4.3.2 AIP inhibition assay in 96-well plate from fractionated natural products 
 
 An aerial ethanol extract of Hydrastis canadensis and a crude chloroform extract 
from a Penicillium fungus were separated on an analytical HPLC into a 96-well plate. A 
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20 µL sample at 10 mg/mL in methanol was injected onto a Gemini-NX  C18 column (250 
x 4.6 mm).  Samples were separated at a 1 mL/min flow rate with fractionation every 15 
seconds.  The gradient was MeOH:Water  from 10:90 to 100:0 over 24 min, yielding a 
total of 60 fractions into the 96-well plate.  The positive control for all inhibition assays 
was an autoinducing cyclic peptide (AIP II) from another strain of S. aureus known to 
disrupt the Agr quorum sensing pathway in S. aureus. 
Mass profiles were generated for each well in each plate. Each well was analyzed 
utilizing an LTQ Orbitrap XL mass spectrometer in the same methodology described 
earlier. The wells were dried down  under air and resuspended in broth inoculated with 
S. aureus USA 300 strain AH1263 after 2 hours of aeration at 300 rpm.   The plate was 
incubated under aeration (300 rpm) for 20 hours with OD600 readings made every 4 
hours to observe growth inhibition. The plate was filtered, and the supernatant was 
analyzed using UPLC-Mass spectrometry in the same manner described for the time-
course study.   
4.3.3 Large scale extraction separation 
 
Pre-weighed air-dried leaves of goldenseal were homogenized using a 
commercial grinder. The ground leaves were percolated with methanol for 24 hr., at 
which time the solvent was removed and replaced with an equivalent volume of 
methanol. The residue-free methanol extract was collected and concentrated in vacuo 
using a rotary evaporator (Heidolph Laborota 4000 Efficient). The methanol extract was 
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re-suspended in 9:1 methanol:water and then partitioned with hexane in a separatory 
funnel. The aqueous methanol layer dried in vacuo and saved while the aqueous layer  
partitioned with 4:1 ratio of chloroform to methanol in water in a separatory funnel. 
The hexane layer was collected, dried in vacuo and was set aside for testing. 
First stage separation was carried out using a normal phase (silica) 
gravitational column and fractions collected based on volume.   The extract was 
mixed with celite, ground into a fine powder and separated using a 
hexane:chloroform:methanol gradient.  The initial gradient was 40:60 
hexane/chloroform and increased to 0:100 after 3 liters were collected.  
Collection was then isocratic at 0:100 hexane:chloroform for another liter after 
which a solvent gradient of 75:25 chloroform:MeOH was initiated and collected 
for an additional 5 liters.   Each liter was assigned a fraction number.  An aliquot 
from each fraction was dried and resuspended at 200 µg/mL with Muller Hinton 
broth and USA 300 AH1263 and tested for AIP inhibition in the same manner 
described above. 
 Second stage chromatography was performed with a Combi Rf flash 
chromatograph (Teledyne-Isco; Lincoln, NE, USA) using a 120 g silica gel column. 
The gradient for this separation was run based on column volume (CV). The 
second stage separation utilized increasing concentration of ethyl acetate 
(EtOAC) in hexane followed by increasing methanol in ethyl acetate up to 100% 
methanol. The flow rate was at 85 mL per minute with total run length of 22.3 
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CV (50.3 min). The initial solvent composition of 100:0 hexane/EtOAc was 
maintained for 0.9 CV (2.03 min) and was then followed by a steep gradient 
change to 0:100 Hexane/EtOAc over 12 CV (27.1 min). The solvent composition 
was held isocratic for 3.10 CV (7.00 min) after which the solvent system was 
switched to MeOH/EtOAc at 3:97 for 1.8 CV (4.06 min) followed by 10:90 over 
1.3 CV (2.93 min), 20:80 over 1.0 CV (2.56 min), and the final gradient at 100:0 
MeOH/EtOAc over 1.0 CV (2.56min), then held isocratic at the same condition 
for 1.2 CV (2.71 min) to wash the column. 
4.4 Results and discussion 
4.4.1 Time-course production of AIP I by MRSA- AH1263 
 
 The goal of this study was to directly measure, quantify, and optimize the 
production of the autoinducing cyclic peptide (AIP I) from MRSA (strain AH1263) using 
ultrahigh performance liquid chromatography (UHPLC) coupled to high resolving power 
mass spectrometry in a time course study. By developing an analytical method to detect 
AIP I directly from S. aureus media, the levels of AIP I production could be quantified.  
Direct quantification provides insight to the amount of AIP I needed to reach 
pathogenesis. 
 The virulent factor AIP I consists of an eight amino acid sequence with a 
thiolactone ring linking the sulfydryl group of the cystine to the α-carboxyl group of the 
C-terminal methionine as shown in Figure 26.  This compound has an exact mass of 
960.37140 Figure 26, and was hypothesized to be detected in the supernatant of 
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filtered MRSA.  AIP I was detectible in both a standard AIP I at 30 µM in Müeller-Hinton 
broth and a filtered spent media after 20 hours of growth (Figure 27).  Retention time 
and the fragmentation pattern of the standard AIP I matched the filtered supernatant of 
the spent media (Figure 28).121   
 
Figure 26. Structure of the cyclic octapetide AIP 1 in its positively charged form. 
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Figure 27A.  UHPLC-MS chromatograms of AIP I standard at a concentration of 31 µM 
in tryptic soy broth (Top) and a filtered supernatant sample from MRSA-AH1263 after 
20 hours incubation in tryptic soy broth. 
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Figure 27B.  The MS/MS sepctrum for AIP I, showing the signature 
fragmentation pattern of the peptide along with its structure.  The thiolactone 
ring remains intact with a mass of 711.2831 confirming the detection of the 
thiolactone ring of AIP I in Figure 27A.121 
 
 
Once it was shown that AIP I could be detected in the spent media, a time-
course study was conducted to determine the optimal growing conditions for 
production of this peptide.   Also, by applying a calibration curve of AIP I to the data 
obtained from the time-course study, the concentration of AIP I could be determined as 
well (Figure 28).   Hypothetically, quantification of AIP I would allow other instruments 
to be utilized for the detection of AIP I as long as they were tuned to detect the peptide 
at the described µM concentrations (20 µM).  By establishing the quantification of AIP I 
production over the course of time, future research may be aided in understanding the 
Agr pathway and the threshold concentration needed to promote virulence in further 
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detail.   The results from this experiment were essential to establish the best conditions 
under which to test for the inhibition of the production of AIP I in 96-well plate assay 
format. 
 
 
Figure 28. Cabration curve of AIP I in tryptic soy broth. 
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Figure 29. The concentration of AIP I produced by Methicillin-resistant S. 
 aureus was measured over a 48 hour time course study.  This plot shows the 
 concentration of AIP I and absorbance vs. time.  
 
 
The time-course study (Figure 29) shows that the production of AIP I begins to 
levels after 20 hr, indicating the optimal growth period for MRSA AH1263. Although the 
bacteria entered lag phase (the point where absorbance does not increase significantly 
over time) at around 8 hours, AIP I production continued to rise steadily until the 20 
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bacteria reach a stationary phase.  This data helped to determine optimization of the 
96-well plate assay described later.   
4.4.2 Method development AIP I inhibition assay in 96-well plate using a Penicillium 
fungus 
 
 The goal of this study is to determine if fractionating a crude concentrated 
extract could indicate compounds responsible for disrupting the Agr quorum sensing 
pathway through inhibiting the production of AIP I.  The purpose is to develop a 
methodology to identify active biological extracts, and to correlate the activity to likely 
constituents within the extract. 
 Dr. Nicholas Oberlies’ lab at the University of North Carolina at Greensboro, 
through the isolation and testing of unique compounds from a Penicillium fungus, 
identified a series of anthraquinones that inhibit AIP I production by MRSA strain 
AH1263 in the µM concentration range (Figure 30).  We employed a crude extract of the 
same Penicillium fungus as a test case for our methodology of identifying quorum 
quenchers.  The goal was to determine if this crude extract could be fractionated into a 
96 well plate and the active molecules identified based on their ability to suppress the 
production of AIP I.  
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Figure 30. Bioactive anthraquinones isolated and identified from a Penicillium fungus 
in the laboratory of Dr. Nicholas Oberlies.  The IC50 values indicate the molar 
concentration needed to observe a 50 % decrease bioluminescence in the lux reporter 
compared to the vehicle control in a gene reporter assay (measured in the laboratory of 
Dr. Alexander Horswill). The amounts isolated from a large scale extract are also 
indicated.  It is important to note that the compounds without labels  have previously 
never been identified.123 
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  After the crude Penicillium extract was fractionated using the analytical HPLC, 
each individual well in the 96-well plate was analyzed using high resolution mass 
spectrometry to develop unique mass profiles.  Four of the bioactive anthraquinones 
isolated by the Oberlies group were identified in high relative abundance in wells 66-74 
(Figure 31).  It is likely that the remaining anthraquinones were present in this range of 
wells, but were undetectable after the single-stage separation process. 
 
 
 
Figure 31. Detection of the anthraquinones from analysis of a Penicillium extract 
fractionated on an analytical HPLC.   Plotted is the relative peak area (for each 
individual anthraquinone separately) vs. well number.  
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 The plate containing the Penicillium fractions was dried down and resuspended 
in tryptic soy broth containing MRSA (AH1263) and incubated under aeration with the 
optimal AIP I producing conditions established above.  This plate was then filtered to 
remove bacteria and relative AIP I levels were measured using mass spectrometry. 
There were some wells (68-71) in which the amount of AIP I was much lower than 
others, suggesting inhibition (Figure 32). The OD600 for all wells were not significantly 
different suggesting no inhibition in the total growth of the bacteria was observed.  
Absorbance was also monitored throughout the growing process in a duplicate plate 
ever 4 hours to ensure no growth inhibition was observed even a “time lag” effect. This 
is important because growth inhibition would lower the production of AIP I and lead to a 
false positive.  Again, AIP II served as the control inhibitor and is represented at the end 
of the well number to indicate a positive control for the inhibition of AIP I production.    
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Figure 32.  AIP I detection in Penicillium fractions incubated with MRSA using UPLC-
MS.  Wells with low levels of AIP I are presumed to contain quorum quenching 
compounds.  A clear suppression of AIP I production was identified from well 68-71.  
 
 
When the data for anthraquinone detection (Figure 31) was overlaid with the 
data for the AIP I detection (Figure 32), it was apparent that the same wells that were 
very active in suppressing the production of AIP I by MRSA also contained the 
anthraquinones that had previously been identified as quorum quenchers (Figure 33).  
Although other constituents from the extract undetectable in the mass spectrometer 
could be responsible for this observed bioactivity, it is hypothesized the anthraquinones 
were the primary inhibitors of the Agr pathway based on their previous characterized 
0.00 
0.50 
1.00 
1.50 
2.00 
0.0E+00 
1.0E+05 
2.0E+05 
3.0E+05 
4.0E+05 
5.0E+05 
6.0E+05 
5
3
 
5
4
 
5
5
 
5
6
 
5
7
 
5
8
 
5
9
 
6
0
 
6
1
 
6
2
 
6
3
 
6
4
 
6
5
 
6
6
 
6
7
 
6
8
 
6
9
 
7
0
 
7
1
 
7
2
 
7
3
 
7
4
 
7
5
 
7
6
 
7
7
 
7
8
 
7
9
 
8
0
 
8
1
 
8
2
 
8
3
 
8
4
 
8
5
 
8
6
 
8
7
 
8
8
 
8
9
 
9
0
 
9
1
 
9
2
 
9
3
 
9
4
 
C
o
n
tr
o
l I
n
h
ib
to
r 
C
o
n
tr
o
l I
n
h
ib
to
r 
C
o
n
tr
o
l I
n
h
ib
to
r 
O
D
6
0
0
 
P
e
ak
 A
re
a 
Well # 
AIP I Absorbance 
105 
 
activities.  More importantly, this correlation of mass profiles to activity verified the 
methodology in detecting possible quorum quenching activity from a complex extract 
separated in a 96-well plate. 
 
 
Figure 33. Overlay of the relative peak areas of the anthraquinones identified 
using the UPLC-MS with the detection of AIP I.  Bioactivity (AIP I suppression) 
correlates with the relative abundance of the anthraquinones, confirming the 
new methodology used to determine AIP I suppression from complex extracts. 
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4.4.3 AIP I Inhibition assay with Hydrastis canadensis after 96-well plate separation 
 
 The purpose of this study was to test the methodology employed with the 
Penicillium fungus to see if we could identify disruption of the Agr quorum sensing 
pathway using a natural product with a known AIP I inhibition effect, but unknown 
constituents responsible for this effect to correlate inhibition to likely bioactive 
constituents. The proposed benefits of implementing this method are as follows: a more 
rapid approach to identifying potential AIP I inhibitors from a complex extract, the 
potential to separate antimicrobial compounds from possible AIP I inhibitors to 
eliminate false positives when testing a crude extract, and the ability to determine if 
activity corresponds to a known constituent of the extract or a previously unidentified 
compound (dereplication).   
It was previously established that a crude methanol extract of the aerial portion 
of Hydrastis canadensis partially inhibited quorum sensing in MRSA sub-growth 
inhibitory concentrations determined by directly measuring AIP I production.124  Our 
ultimate goal is to identify the quorum quenching compound(s) responsible for the 
activity of this crude extract.  By implementing the same methodology as in the previous 
experiment with the Penicillium fungus, we showed there were significant decreases in 
AIP I production by MRSA-AH1263 after the crude extract was separated using the 
analytical HPLC into a 96-well plate (Figure 34).   Also, since the separated extract of 
Hydrastis canadensis was analyzed using the high resolution mass spectrometer before 
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being tested in the inhibition assay, mass profiles for each well were measured and 
could be compared with AIP I inhibition results. 
 
 
Figure 34. 96-well plate separation of Hydrastis canadensis using analytic HPLC AIP I 
detection using UPLC-MS.  The lower the level of AIP I Peak area detected the more 
disruptive those wells were to the Agr quorum sensing pathway.  A clear large 
suppression of AIP I production was identified towards the beginning of separation wells 
between wells 9 to 22.  The figure also shows OD600.  It was determined there was no 
growth inhibition of the bacteria based on the no significant decrease in absorbance 
amongst wells during the growth of the bacteria. 
 
 
 After observing the suppression of AIP I production, possible masses unique to 
the wells with activity were correlated with activity (Figure 35).  Furthermore, by using a 
high resolution mass spectrometer (Orbi-trap) molecular formula could be determined 
for the masses corresponding to activity. The known antimicrobial alkaloid berberine 
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was also plotted to show AIP I suppression did not correspond its antimicrobial 
properties.  This however was not the case when the OD600 was monitored during the 20 
hour incubation period every 4 hours. The wells containing the berberine (wells 4-7) 
showed a time lag in growth reaching the lag phase around 12 hours as opposed to 8 
hours for the rest of the wells. 
 
Figure 35.  Plotted are the unique masses in relative abundance corresponding to AIP I 
suppression.  Molecular formulas were determined using accurate mass data from the 
Orbi-trap mass spectrometer.  The abundance of berberine a known antimicrobial 
alkaloid is also shown.  The control inhibitor is shown on the later part of the graph in 
the final wells. 
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 Through this experiment, we detected likely inhibitors of the Agr quorum sensing 
pathway that would be interesting to isolate from a large scale extraction. In wells 8-10 
a compound with the mass of 209.00880 ([M-H])- corresponded with bioactivity by 
increasing in peak while the relative peak area of AIP I decreased. The chemical formula 
was determined to be C9H5O6
- with a +0.2 ppm error, and the formula in the neutral 
form had seven hits when searched against the Dictionary of Natural Products. For wells 
10-14 a significant activity was observed corresponding to a mass of 352.11169 ([M-H]-). 
Its chemical formula was determined to be C20H18N1O5
- (+ 3.2 ppm error) and returned 
zero hits when search against the Dictionary of Natural Products in its neutral form. The 
activity for wells 17-20 correlated with an observed mass of 305.24687 ([M+H]+).  Its 
formula was calculated to be C20H33O2
+ (- 2.4 ppm mass accuracy) and when searched 
returned 743 hits.  For wells 22-24, a mass of 625.26288 corresponded with AIP I 
suppression.  The calculated formula determined to be C32H33N10O5 ([M+H]+)   (-4.6 ppm 
mass accuracy) with zero hits when searched. None of the masses searched in the 
Dictionary of Natural Products corresponded with previously reported constituents of 
Hydrastis canadensis. Thus, it was determined through these experiments that the 
bioactivity did not correspond to known constituents found in H. canadensis, and 
therefore it was determined a large scale bioactivity-guided isolation process would be 
worth pursuing.   
 A limitation of the data shown in Figure 35 is that it is difficult to discern which 
wells cause a statistically significant suppression in AIP I production, and which are 
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simply random fluctuations in AIP I levels.  To verify those fractions that showed 
inhibition of AIP I production in the 96-well plate, samples from the wells that seemed 
to be active in Figure 35 were analyzed in triplicate with a separate assay (Figure 36).  
Most wells corresponding to AIP I suppression from the 96-well assay were confirmed as 
active. Fractions 16 and 24 did not exhibit statistically significant activity (p values = 
0.83, and 0.25 respectively) whereas fractions 9, 13 and 19 did as shown in Figure 36 p-
values (0.001, 0.007, 0.015 respectively).   Significant difference was determined using a 
single factor ANOVA test compared to the control with a p < 0.05 considered significant. 
We used this information in the large scale extraction process to focus on compounds 
that corresponded to activity in the 96-well plate assay to guide the isolation process. 
 
  
Figure 36.  Shown in the figure are fractions in the 96-well plate assay that were 
observed to inhibit AIP I production run in triplicate.  Fractions 9, 13, and 19 were 
determined to disrupt the Agr quorum sensing pathway while fractions 16 and 24 did 
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 To further validate the new assay, several of the same fractions tested for AIP 
inhibition to the laboratory of Dr. Horswill to test in the lux gene reporter assay 
described previously described (Figures 37-44).122  In this assay they measured the 
OD600 and the relative bioluminescence dependent on the concentration of the various 
fractions.  The analysis was run in triplicate and confirmed some of the results obtained 
in the 96-well plate assay.  Both active and inactive fractions determined in the 96-well 
plate assay were tested to confirm methodology.  Also, a vehicle control and the crude 
plant extract were analyzed for a bioactivity comparison. 
 
 
 
Figure 37.  Vehicle control for the gene reporter bioluminescence assay run in 2% 
DMSO.  Plotted is absorbance and luminescence run in triplicate.  
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Figure 38.  Crude Hydrastis canadensis extract dissolved in broth and 2% DMSO in the 
gene reporter assay.  Luminescence and OD600 were plotted as a function of 
concentration. 
 
 
 As the concentration of the plant extract increased the luminescence decreased 
suggesting there is disruption of the quorum sensing pathway (Figure 38).  Decrease in 
luminescence began at a low concentration 5 µg/mL and continued to decrease to 1000 
µg/mL.   Based on the OD600 readings at 1000 µg/mL the extract inhibited the growth 
of the bacteria.  At this concentration of crude plant extract the antimicrobial 
concentrations are high enough to inhibit the growth. This growth inhibition confounds 
the quorum quenching results, but only at high concentrations. 
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Figure 39.  Fraction 4 dissolved in broth and 2% DMSO in the gene reporter assay.  
Luminescence and OD600 were plotted as a function of concentration. 
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Figure 40.  Fraction 6 dissolved in broth and 2% DMSO in the gene reporter assay.  
Luminescence and OD600 were plotted as a function of concentration. 
 
 
Fractions 4 and 6 had no antimicrobial effect or quorum quenching effect as the 
concentration increased (Figures 39-40).   This corresponds to the same result achieved 
in the 96-well plate assay.  Although this fraction contained the known antimicrobial 
alkaloid berberine, the highest concentration tested (100 µg/mL expressed as dry 
extract weight per assay volume) was not a high enough concentration to significantly 
inhibit growth.  Based on the results from this assay fraction 4 was not of interest for 
the identification of quorum quenching or antimicrobial compounds. 
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Figure 41.  Fraction 9 dissolved in broth and 2% DMSO in the gene reporter assay.  
Luminescence and OD600 were plotted as a function of concentration. 
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Figure 42.  Fraction 12 dissolved in broth and 2% DMSO in the gene reporter assay.  
Luminescence and OD600 were plotted as a function of concentration. 
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Figure 43.  Fraction 4 dissolved in broth and 2% DMSO in the gene reporter assay.  
Luminescence and OD600 were plotted as a function of concentration. 
 
 
As the concentration of Fractions 9 and 12 and 22 increased, the luminescence 
decreased while the OD600 did not vary suggesting a quorum quenching effect and not 
an antimicrobial effect (Figures 41-43).  In the 96-well plate assay, fraction 9, 12, and 22 
also showed quorum quenching activity without lowering the absorbance (Figure 34).  
The verification of these results using the lux gene reporter assay confirmed the validity 
of AIP I inhibition assay as a means to evaluate quorum quenching. 
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Figure 44.  Fraction 24 dissolved in broth and 2% DMSO in the gene reporter assay.  
Luminescence and OD600 were plotted as a function of concentration. 
 
 
 Interestingly, as fraction 24 (Figure 44) increased in concentration, the 
luminescence decreased while no antimicrobial activity was observed.  This did not 
correspond with the 96-well assay results.  The reason for this discrepancy is most likely 
due to low concentrations of the active constituent in Fraction 24. In the lux gene 
reporter assay, tests were performed at a range of concentrations, whereas the 96-well 
plate assay, which was based on analytical HPLC separation, the concentration range of 
each well is between  0.01 – 2.00 µg/mL which is at much lower concentrations.    Based 
on the fluorescence assay fraction 24 is of interest in disrupting the Agr quorum sensing 
pathway.   
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4.4.4 Large scale bioactivity guided fractionation of Hydrastis canadensis 
 
 The goal of this experiment was to isolate the constituents in a large methanol 
extraction of Hydrastis canadensis that were responsible for the AIP I inhibition 
observed in the previous section.  From a flash chromatography separation on the silica 
gel column, a total of 9 pooled fractions were collected and tested for AIP suppression 
(Figure 45).  It was determined fractions 1, 2, 3, and 4 caused significant suppression of 
AIP based on single factor (p-values, 0.02, 0.01, 0.03, 0.04 respectively).  Therefore, 
fraction 2 was subjected to a second stage of fractionation using a 
heaxane:ethylacetate:methanol gradient as described in Section 4.3.3.112    
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Figure 45.  Suppression of AIP I production by fractions pooled from the flash 
chromatography separation with hexane:chloroform:methanol with an ethanolic 
aerial extract.  Fractions 1,2,3, and 4 were determined to be partial AIP I inhibitors.  
Fraction 2 contained the majority of compounds hypothesized as quorum quenchers 
from the study described in Section 4.4.3. 
  
 
The fractionation process using hexane:ethylacetate:methanol of fraction 2 
yielded a total of 13 subfraction (Figure 46).  The results from this assay showed 
subfractions 3-9 to be bioactive by being statistically lower than the vehicle control 
using single factor ANOVA analysis with p value < 0.05 and fractions 11-13 to be inactive 
in suppressing the production of AIP I.   Further stages of separation are necessary to 
verify the constituents responsible for activity. 
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Figure 46.  Suppression of AIP I production in the Agr quorum sensing pathway of 
MRSA-AH-1263.  Bioactivity was determined based on the lower total peak area for the 
selected ion chromatogram corresponding to AIP I.  Subtractions 3-9 and the positive 
control (AIP II) caused a statistically significant suppression in AIP I production compared 
to the vehicle control. Statistical analysis was based on single variable single factor 
ANOVA analysis with p value < 0.5 considered significant. 
 
 
4.5 Conclusion 
 
 Through the implementation of UPLC-HRMS it was determined that the 
production of AIP I from MRSA can be directly monitored by analyzing the bacteria 
culture supernatant.  Compared to previous methods, this methodology is an 
improvement by allowing a product of the Agr quorum sensing pathway to be directly 
monitored and quantified as opposed to a downstream bioluminescence reporter in the 
lux assay.  Also, by establishing a calibration curve to measure the concentrations this 
0 
0.5 
1 
1.5 
2 
0.E+00 
1.E+06 
2.E+06 
3.E+06 
4.E+06 
5.E+06 
6.E+06 
O
D
6
0
0
 
P
e
ak
 A
re
a 
AIP I Production 
Absorbance 
* * 
* 
* * 
* 
* 
122 
 
method has the potential to be used to determine bioactive levels of AIP I necessary to 
elicit toxin production and pathogenesis in vivo.   
 By growing MRSA in a time course study and measuring absorbance and the AIP I 
levels in the supernatant as a function of time, the conditions that optimized AIP I 
production were established.  This enabled measurements to be made of the 
suppression of AIP I production when MRSA was combined with extracts from natural 
products, thereby identifying those extracts with quorum quenching activity.  The 
methodology could be implemented on a variety of natural products and pure 
compounds to help identify possible therapeutic agents that could be employed to 
inhibit pathogenesis of MRSA. 
 Through the separation of crude extracts from natural products into a 96-well 
plate, key constituents within a complex extract could be identified as quorum 
quenchers.  This assay can prevent the isolation of already known compounds while at 
the same time identify interesting candidates for bioactivity.  Specifically for Hydrastis 
canadensis, the antimicrobial compounds were separated from the quorum quenching 
fractions preventing the possibility of false positives. In the future this could make the 
isolation process more efficient by applying a mass-guided separation methodology to 
isolate compounds of interest as opposed to performing traditional bioactivity-guided 
separation.  It is important to note, however, that a limitation of MS is the inability to 
confirm structure for truly unknown compounds.  Searches against the Dictionary of 
Natural Products returned many hits for some compounds, and no hits for others.  
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Neither of these results makes confirmation of structure possible, and large scale 
isolation for NMR analysis is still necessary for structure elucidation and confirmation of 
biological activity. 
 Based on the 96-well screening of the crude natural product extracts we were, 
however, able to determine whether a large scale isolation process was worthwhile.  
First, we were able to identify if there was any bioactivity associated with the extract.  
Second, by taking the OD600 we were able determine whether or not that activity is 
antimicrobial or quorum quenching. Importantly, quorum quenching compounds could 
be separated by antimicrobial compounds, which would otherwise have confounded the 
results of the quorum quenching assay. Third, we could identify likely candidates that 
correspond to the activity by analyzing the mass profiles of each well, and fourth and 
finally, we could use accurate mass to determine whether those compounds have 
already been identified as components of H. canadensis.   
 Future aims in this research include the isolation and structure elucidation of 
quorum quenchers from H. canadensis.   Through the established methodology, 
bioactivity can be measured through the fractionation process until a single compound 
is isolated.  Furthermore, many different natural product extracts are being tested for 
quorum quenching activity using the 96-well plate assay.   
 In addition to identifying specific compounds, the mode of action in which H. 
canadensis and other AIP I inhibitors are being investigated.  Through using various 
MRSA strains with deleted AgrC or AgrB receptors, it can be determined if the 
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exportation of AIP I and/or the reuptake of AIP I is being inhibited.  Better 
understanding of the mode of action in which quorum quenchers inhibit AIP I 
production could facilitate the development of new therapeutic agents to treat MRSA 
infections.    
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